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Abstract
THE GLUCOCORTICOID-INDUCED LEUCINE ZIPPER AND
IMMUNOMODULATION IN EXTRACORPOREAL PHOTOCHEMOTHERAPY.
Jeffrey S. Futterleib, Robert E. Tigelaar, Jaehyuk Choi, Richard L. Edelson.
Department of Dermatology, Yale University School of Medicine, New Haven, CT.
Extracorporeal photochemotherapy (ECP) induces antigen-specific immune
tolerance in graft-versus-host disease and solid-organ transplant rejection, and involves
the ex vivo exposure of peripheral blood mononuclear cells to 8-methoxypsoralen plus
ultraviolet A light (PUVA). In this study, we developed an in vitro model of ECP to
decipher the immunomodulatory mechanisms of PUVA. The glucocorticoid-induced
leucine zipper (GILZ) is both necessary and sufficient for the generation of
dexamethasone-induced tolerogenic dendritic cells (DCs). We hypothesized that PUVAinduced activation of GILZ may contribute to the immune tolerance observed after ECP
therapy in graft-versus-host disease and solid-organ transplantation. We report that
PUVA acts via two pathways culminating in GILZ up-regulation in human monocytederived dendritic cells (MoDCs). Firstly, PUVA directly induces GILZ expression in
MoDCs in a dose-dependent fashion (p < 0.01). Secondly, PUVA acts indirectly through
the generation of apoptotic lymphocytes to induce GILZ expression in an apoptotic cell
dose-dependent fashion (p < 0.01). MoDCs treated with PUVA, and/or exposed to
lymphocytes rendered apoptotic by PUVA, up-regulated GILZ, down-regulated CD80,
CD86 and CD83, became resistant to LPS-induced maturation, increased IL-10
production, and decreased production of pro-inflammatory cytokines (IL-12, IFN-γ, IL-6,
TNF-α), and chemokines (IL-8, MCP-1, MIP-1β, RANTES) (all p < 0.05). Knockdown
of GILZ via transient transfection with GILZ siRNA, compared to scramble siRNA,
reduced IL-10 production and increased IL-12 production, demonstrating that GILZ is
necessary for generating this tolerogenic cytokine profile. This study uncovers a
potential molecular explanation for the immunomodulatory effects of PUVA, specifically
through the induction of GILZ and polarization of immature MoDCs into tolerogenic
DCs, and has implications for better understanding how ECP induces antigen-specific
immunosuppression in vivo.
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Introduction
1.1. Ultraviolet Radiation
Ultraviolet (UV) radiation possesses potent immunosuppressive and antiinflammatory properties that were only fully appreciated with the advent of molecular
immunology (1). In 1974, Kripke first demonstrated that immunologic rejection of UVinduced murine skin tumors, transplanted into syngeneic mice, could be limited by
irradiating the recipient animal with low-dose UV light (2). Moreover, tumor graft
rejection could also be prevented by adoptively transferring T-lymphocytes from UVirradiated mice into recipient animals (2). This finding suggested a systemic component
to the immunosuppressive action of UV radiation, and ultimately led to the discovery of
antigen-specific suppressor T-lymphocytes induced by UV radiation (3). Subsequently,
UV radiation was shown to directly inhibit various antigen-presenting cells (APCs) of the
skin (4), including Langerhans cells (5), demonstrating the capacity of UV radiation to
modulate both the innate and adaptive immune response.
Given its higher energy content, UVB radiation (280-320 nm) acts directly on
DNA, forming pyrimidine dimers, photo-products, and ultimately inducing programmed
cell death (1). In contrast, UVA radiation (320-400 nm) is less energetic, and requires the
use of photosensitizing agents to achieve similar cellular effects (1). In 1953, Lerner
characterized a psoralen as the photoactive compound responsible for the
photosensitizing properties of the Ammi majus plant (1). Approximately twenty years
later, the combination of oral psoralens and UVA light was introduced for the treatment
of psoriasis (6). Then in 1987, Edelson et al. developed extracorporeal
photochemotherapy (ECP), a novel therapy derived from psoralens and UVA light, to
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treat cutaneous T-cell lymphoma (CTCL) (7). Since its initial FDA approval for CTCL,
ECP has also been shown to be an efficacious, glucocorticoid- and immunosuppressantsparing treatment for a variety of diseases, including graft-versus-host disease (GVHD)
(8), solid-organ allograft rejection (9), and autoimmune disease (10).

1.2. Extracorporeal Photochemotherapy
ECP consists of the ex vivo exposure of peripheral blood mononuclear cells
(PBMC) to the photosensitizing agent 8-methoxypsoralen (8-MOP) and UVA light (now
referred to as PUVA), followed by subsequent reinfusion into the patient (7). 8-MOP
quickly penetrates cellular and nuclear membranes, and upon absorption of UVA light,
forms DNA mono-adducts and intra-strand cross-links in a PUVA dose-dependent
fashion (11). The resultant DNA damage blocks replication and transcription and
culminates in a well-characterized pattern of lymphocyte apoptosis (12-14). An intrinsic
apoptotic pathway is initiated within 20 minutes of exposure to PUVA, involving reactive
oxygen species formation, damage to mitochondrial membranes, and capsase-3, -8, and
-9 activation (15-17). Progressive lymphocyte apoptosis is observed over the course of
48 hr (16, 17), primarily mediated through an extrinsic apoptotic pathway involving FasL
and Fas receptor (CD95) interactions (18).
Therapeutic doses of 8-MOP and UVA light were initially titrated for clinical use
based on their ability to inhibit lymphocyte proliferation in vitro (19, 20), and doses
generally range from 1 to 2 J/cm2 of UVA light and 100 to 200 ng/mL of 8-MOP (6-8).
At these therapeutic doses, approximately 50 to 60% of lymphocytes are rendered
apoptotic 24 hr after PUVA treatment, and 70 to 90% have reached a stage of late
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apoptosis by 48 hr (21). The effects of PUVA on APCs are more ambiguous, with some
studies documenting a resistance (12, 21-23), and others a sensitivity (24-26), to
apoptosis following PUVA treatment.
A persistent mystery surrounding ECP centers on how a single therapy can
stimulate an immune response to target and eradicate malignant lymphocytes in patients
with CTCL (27), while also suppress the immune response of auto-reactive lymphocytes
in patients with GVHD, allograft rejection and autoimmune disease (28)? Although a
unifying mechanism fully explaining ECP’s clinical efficacy has not yet been described,
modulation of dendritic cells (DCs) (24, 29, 30), induction of regulatory T-lymphocytes
(Tregs) (24, 30, 31), lymphocyte apoptosis (12-14), and modulation of cytokine release
(32, 33) have all been implicated.

1.3. Dendritic Cells
DCs are versatile APCs capable of eliciting robust immune responses to
pathogenic and foreign antigens, while maintaining tolerance to benign and self-antigens
(34-36). The decision to elicit a specific type of immune response depends on multiple
factors, including the maturation state of the DC (37, 38), the profile of co-stimulatory
molecule expression and cytokine secretion, the nature of the pathogenic stimulus, the
antigen dose presented, and the milieu of the tissue microenvironment (34-38).
Classically, DCs mature after exposure to various danger and pro-inflammatory
mediators, including danger-associated molecular patterns (DAMPs) and pathogenassociated molecular patterns (PAMPs) (34, 35). DAMPs and PAMPS are recognized by
a variety of pattern recognition receptors, including Toll-like receptors (TLRs) (34, 35).
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Mature DCs up-regulate antigen-presenting molecules, express high levels of costimulatory molecules, such as CD80 and CD86, and secrete pro-inflammatory cytokines,
such as IL-12 (35). Mature DCs present peptides on major histocompatibility complex
(MHC) class II molecules, and engage naïve T-lymphocytes through the T-cell receptor
(TCR) (34, 35). Mature DCs effectively deliver the necessary second signals (e.g.
CD80/CD86 through CD28), and third signals (e.g. IL-12, IFN-γ, Notch ligand) required
for naïve T-lymphocytes to differentiate into effector T-lymphocyte subsets (e.g Th1, Th2,
Th17), thereby generating diverse immunogenic responses (34, 35). Maturation also
regulates the life span of DCs through CD14-mediated nuclear factor of activated Tlymphocyte (NFAT) activation, leading to the initiation of DC apoptosis (39).

1.4. Tolerogenic Dendritic Cells
In contrast, tolerogenic DCs are semi-mature cells (37, 38), generally characterized
by low expression of co-stimulatory molecules, active production of IL-10 and TGF-β,
and reduced production of pro-inflammatory cytokines and chemokines (36, 40).
Tolerogenic DCs are critical in promoting tissue homeostasis and maintaining peripheral
tolerance to harmless foreign antigens, as well as to self-antigens (36, 41). Since their
initial characterization, many agents have been investigated, with varying success rates,
to promote the in vitro differentiation of tolerogenic DCs for therapeutic purposes in
treating autoimmune diseases and allograft rejection (36, 40, 41). Growth factors,
including the immunosuppressive cytokines IL-10 and TGF-β, vitamins A and D3,
prostaglandin E2, and retinoids have all been utilized (36, 40, 41). Various
immunosuppressive drugs have also been studied, including glucocorticoids,
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cyclosporine, and tacrolimus (36, 40, 41), and protocols for genetically modifying
immature DCs using viral vectors have been developed (40).
Immune tolerance to self-antigens begins during development through mechanisms
of central tolerance occurring primarily in the thymus (36). Through the process of
central tolerance, DCs and medullary epithelial cells delete the majority of Tlymphocytes expressing TCRs with strong affinities for peptides derived from selfproteins (36, 42). In addition, some self-reactive naïve T-lymphocytes are thought to
differentiate into Tregs, known as natural Tregs (42). Central tolerance mechanisms are
overwhelmingly successful in preventing the vast majority of autoimmune disease (42).
Nevertheless, some auto-reactive T-lymphocytes escape the thymus and enter peripheral
tissues (42). Tissue damage and cellular necrosis, resulting from periods of inflammation
and infection, release self-proteins that are not adequately represented in the thymus and
which T-lymphocytes may potentially target in an auto-reactive fashion (41, 42).
Peripheral tolerance mechanisms are then required to suppress immune responses to these
exposed self-antigens, as well as to harmless foreign antigens, non-pathogenic
commensal organisms in the lung and digestive tract, and antigens in immunologically
privileged sites, such as the anterior chamber of the eye and testes (41).
To maintain peripheral tolerance to these antigens, tolerogenic DCs induce autoreactive T-lymphocyte deletion and anergy, and also generate antigen-specific Tregs (36,
41, 42). Tolerogenic DCs present peptides on MHC-class II molecules, and in a similar
manner as immunogenic DCs, engage naïve T-lymphocytes through the TCR (36, 41).
However, TCR ligation and downstream signaling in the setting of limited, or absent,
second signals (e.g. low CD80/CD86 to engage CD28) and third signals (e.g. low IL-12),
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results in T-lymphocyte deletion or anergy (40-42). Deleting auto-reactive Tlymphocytes, or rendering them anergic and unable to respond to the presented antigen in
future settings, enables tolerogenic DCs to establish peripheral tolerance to the presented
antigens (41, 42). Furthermore, Tregs are critically important in maintaining peripheral
tolerance, and generally are CD4+CD25+ T-lymphocytes expressing the Foxp3
transcription factor (43). Tolerogenic DCs present peptide in the context of active IL-10
and TGF-β secretion (42, 43), rendering them uniquely capable of generating antigenspecific Tregs both in vitro and in vivo (43, 44).
Multiple lines of evidence suggest that the induction of antigen-specific Tregs by
tolerogenic DCs contributes to the therapeutic efficacy of ECP (24, 31). Firstly, in vivo
murine models of ECP demonstrate that an infusion of ECP-treated donor cells
significantly reduces established GVHD (45) and prolongs cardiac allograft survival (46,
47), through the generation of antigen-specific CD4+CD25+Foxp3+ Tregs (45, 47). In the
GVHD model, Gatza et al. report that in addition to increased numbers of Foxp3+ Tregs
derived from the donor’s T-lymphocytes and bone marrow grafts, there was a
corresponding decrease in the number of donor effector lymphocytes that had never been
themselves exposed to PUVA (45). Thus, through both donor effector T-lymphocyte
deletion and Treg formation, the donor’s T-lymphocytes were rendered tolerant of
foreign antigens within the recipient animal (45). In the cardiac allograft models, ECPtreated donor cells similarly delivered both donor alloantigen and regulatory signals to
DCs of the transplant recipient (46, 47). The systemic anti-donor T- and B-lymphocyte
responses were greatly decreased, in part through T-lymphocyte deletion and Treg
induction, and tolerance to foreign antigens in the allogeneic graft was achieved (46, 47).
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Secondly, ECP inhibits both the sensitization and effector phase of contact
hypersensitivity, through the induction of Tregs and generation of IL-10, respectively
(48). Thirdly, ECP was accompanied clinically by an increase in the percentage of
circulating CD4+CD25+Foxp3+ Tregs, from 8.9% to 29.1%, in ten patients with GVHD
(49). Lastly, prolonged ECP has not been observed to increase the incidence of
opportunistic infection or malignancy (24), and T-lymphocyte and B-lymphocyte
responses to novel or recall antigens are conserved in ECP patients (50). Both of these
observations suggest that antigen-specific effects, rather than global immunosuppression
as seen with chronic glucocorticoid administration, are operating in vivo after ECP.
Classically, tolerogenic DCs were described as both phenotypically and
functionally immature cells (36, 37). The original model by Steinman et al. stated that
immature DCs present low levels of self-peptide in the context of low co-stimulatory
molecule expression, and thereby mediate tolerance to self-antigens (34-36). This model
was subsequently refined with the discovery of co-inhibitory molecules (37), including
B7-H1 (programmed death ligand 1) and immunoglobulin-like transcript 3 (ILT-3), and
with the realization that tolerogenic DCs actively secrete immunosuppressive molecules,
including IL-10 and TGF-β (38). It is now evident that tolerogenic DCs are both
phenotypically and functionally mature cells and perform specialized functions,
analogous to immunogenic DCs (37, 38, 40). Thus, the paradigm of DC maturation as
the critical switch between tolerance induction and immunity is no longer strictly valid.
The term ‘semi-mature,’ has been coined to differentiate the unique phenotypic and
functional characteristics of tolerogenic DCs from immunogenic DCs (37, 38).
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Apart from the questionable susceptibility of monocytes and DCs to apoptosis
following ECP (12, 21-26), only a handful of studies have investigated the direct effects
of ECP on monocyte and DC function. Studies examining the effects of ECP on these
cell types have relied on procuring cells after treatment, or by irradiating cells in vitro
using a UV light box. In one study, irradiated leukocytes from patients with chronic
GVHD were isolated from the ECP bag after treatment (51). When these irradiated
leukocytes were co-cultured with monocytes isolated before ECP from the same patient,
production of both IL-10 and IL-1 receptor antagonist (IL-1Ra) were markedly increased
(51, 52). Increased IL-10 production by monocytes was also observed following ECP in
a separate analysis (23), along with reduced CD54, CD40 and CD86 co-stimulatory
molecule expression (23). Likewise, an in vitro model of ECP designed by Legitimo et
al. consisted of the co-culture of PUVA-treated monocytes with untreated monocytes in a
nine to one ratio in an attempt to reproduce the extracorporeal exposure of approximately
10% of circulating monocytes to PUVA (53). In this model, the authors observed
increased HLA-DR expression and endocytic capacity in the untreated monocytes, and a
reduced ability to induce allogeneic T-lymphocyte proliferation (53).
Concerning the effects of ECP specifically on DC function, Spisek et al. analyzed
myeloid DCs isolated from photopheretic products before reinfusion into patients with
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refractory chronic GVHD (21). The authors reported significant production of IL-10, and
virtually no IL-6 or IL-12 production by myeloid DCs after treatment (21). Another
study also reported a decreased alloreactive capacity of DCs isolated after ECP (54), and
a shift from a predominately Th1 (IFN-γ) to Th2 (IL-10 and IL-4) cytokine profile in
patients with chronic GVHD (54). Finally, Berger et al. demonstrated that the ECP
procedure itself induces monocyte-to-DC differentiation within a single day (29). The
DCs produced during ECP were maturationally synchronized and functionally capable
APCs (29), further suggesting that DCs play a central role in the therapeutic efficacy of
ECP.

1.5. Glucocorticoid-Induced Leucine Zipper
Glucocorticoids have long been known to modulate APC function both in vitro and
in vivo (55). Human DCs treated with dexamethasone increase mannose-receptor
mediated endocytosis (56), reduce expression of the maturation molecule CD83 and the
co-stimulatory molecule CD86 (55), increase production of IL-10 (57), and reduce
production of IL-12 (57). Dexamethasone treatment also induces durable effects, with
increases in IL-10, and decreases in IL-12, maintained for up to 5 days after removal of
dexamethasone from DC cultures (58).
Until recently, the molecular signals driving an immature DC to be committed
towards a tolerogenic phenotype and functional state were unknown. In 2006, Cohen et
al. described an intracellular gene and protein product, highly expressed in human DCs
after dexamethasone treatment, that was pivotal for the tolerogenic functions of DCs (59).
The gene, called the glucocorticoid-induced leucine zipper (GILZ, also known as TSC22
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domain family protein 3), was originally identified as a dexamethasone-responsive gene
that protected murine T-lymphocytes from TCR/CD3-activated cell death (60). Tlymphocytes over-expressing GILZ demonstrated pronounced inhibition of TCRactivated nuclear factor κB (NF-κB), IL-2 production, FasL up-regulation, and ultimately
activation-induced apoptosis (61). A variety of immunologic and non-immunologic cell
types were subsequently discovered to also express GILZ, including macrophages (62),
mast cells (63), bone marrow mesenchymal cells (64), and epithelial cells (65, 66). To
date, GILZ has been implicated in an equally diverse number of cellular processes,
including spermatogenesis (67), renal ion transport (65, 66), neuroendocrine functioning
(68), and osteogenic differentiation (64).
In the original report by Cohen et al., over-expression of GILZ by plasmid
transfection, and silencing of GILZ with siRNA revealed that GILZ is both necessary and
sufficient for the generation of tolerogenic human DCs (59). The expression of GILZ is
also induced in vivo in patients receiving glucocorticoids (59). In a follow-up study by
Hamdi et al., human DCs expressing GILZ were found to be capable of inducing antigenspecific Tregs, and GILZ was necessary for this induction (69). The authors postulated
that GILZ may be a molecular switch committing immature DCs towards the tolerogenic
differentiation pathway (59, 69) . According to this model, immature DCs do not express
GILZ until exposed to immunosuppressive stimuli, such as glucocorticoids, IL-10, or
TGF-β (59). Once GILZ is expressed at high levels, immature DCs differentiate into
semi-mature tolerogenic DCs capable of generating Tregs and maintaining immune
tolerance (59, 69). If immature DCs are instead exposed to traditional maturation stimuli,
including inflammatory, microbial or danger signals, they do not express GILZ and
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differentiate into mature immunogenic DC, capable of eliciting classical Th1, Th2, Th17 or
cytotoxic T-lymphocyte immune responses (34-36).

Human DCs expressing GILZ down-regulate co-stimulatory molecules and
maturation markers (59, 70, 71), up-regulate molecules involved in maintaining
peripheral tolerance, including PD-L1 and ILT-3 (70, 71), increase production of IL-10,
reduce production of pro-inflammatory cytokines and chemokines, and are poor inducers
of CD4+ effector T-lymphocyte responses (59, 69-71). In addition, human DCs
expressing GILZ generate IL-10 producing CD4+CD25+Foxp3+ Tregs, capable of
inhibiting CD4+ and CD8+ T-lymphocyte responses in an antigen-specific manner (69).
In fact, the antigen-specific tolerance-inducing capacity of GILZ is exerted mainly
through Treg induction (69-71).
In humans, GILZ codes for a cytosolic protein that directly binds to, and inhibits, a
wide variety of signaling pathways that are highly active during inflammation, and in
immunogenic DCs after ligation of TLRs, cytokine receptors, and chemokine receptors
(70, 71). Specifically, GILZ binds to the p65 subunit of the prominent pro-inflammatory
transcription factor NF-κB, preventing its nuclear translocation, DNA binding capacity,
and transcriptional activity (72). GILZ also inhibits the mitogen activated protein kinase
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(MAPK) family members Ras/Raf-1 (61, 67, 71), and ERK-1/2 (70, 71), and the activator
protein 1 (AP-1) (70, 71). Given the importance of signal transduction pathways in
integrating and amplifying cellular responses to pathogens and pro-inflammatory
cytokines, the role of GILZ as a direct inhibitor of these pathways points towards its
fundamental role as a regulator of the immune response (70, 71).
The expression of GILZ is induced to a lesser extent by both IL-10 and TGF-β
(59). Like glucocorticoids (55-58), IL-10 blocks the maturation of DCs, reducing the
expression of co-stimulatory molecules and the production of IL-12 (73), and TGF-β is
critical for Treg induction (43). These observations suggest that GILZ may be a common
molecular switch committing DCs towards a tolerogenic phenotype and functional state
after exposure to diverse immunosuppressive stimuli (59, 69). While glucocorticoids
bind to the glucocorticoid receptor, which transactivates the expression of glucocorticoid
target genes including GILZ (70, 71), the molecular pathways linking IL-10 and TGF-β
signaling to the induction of GILZ remain unknown.

1.6. Apoptotic Cells
The uptake of apoptotic cells by resident DCs not only maintains tissue
homeostasis, but is also thought to induce peripheral tolerance through the presentation of
self-antigens derived from apoptotic cells (41, 42). The ability of apoptotic cells to
deliver immunosuppressive signals to APCs and reduce a pro-inflammatory response is
also well documented (74-76). The extent of immunosuppression conferred by apoptotic
cells depends on the nature of the apoptotic material (75, 76), the level of cellular
destruction, ranging from early apoptosis to necrosis (77), and the route of apoptotic cell
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administration (74, 75). Voll et al. first reported that monocytes, in the presence of
apoptotic cells, increase production of IL-10 and decrease production of the proinflammatory cytokines TNF-α, IL-1β and IL-12 (74). Cell-contact was later
demonstrated to be necessary for the induction of this immunosuppressive cytokine
response (75). Moreover, monocytes cultured with ECP-treated apoptotic lymphocytes
reduce production of the pro-inflammatory cytokines IL-1α (21, 32) and IL-6 (21, 32),
and increase production of IL-10 (23, 52) and IL-1Ra (51, 52).
Similarly, apoptotic cells have been observed to modulate the functions of both
macrophages (78) and DCs (77-79). Immature DCs are capable of recognizing and
internalizing PUVA-treated cells undergoing apoptosis (31, 45-47). After internalizing
apoptotic cells, DCs acquire a tolerogenic phenotype (53, 80, 81), down-regulate
expression of co-stimulatory molecules (80, 81), increase production of IL-10 (48, 79,
81), and become poor stimulators of naïve T-lymphocytes (79-81). The downstream
molecular pathways contributing to the induction of tolerogenic DCs by apoptotic cells
remain unclear, however receptors involved in the recognition and uptake of apoptotic
bodies are likely involved (74).
The exposure of phosphatidylserine on the outer leaflet of the plasma membrane
and loss of membrane phospholipid asymmetry is one of the earliest cellular events
occurring during apoptosis (82, 83). Phosphatidylserine is recognized by TAM (Tyro3,
Axl and Mer) receptors on the surface of DCs (84), and through a combination of the
thrombospondin receptor (CD36) (78) and other scavenger receptors, including the
vitronectine (αVβ3 integrin) receptor (74), DCs recognize and internalize apoptotic cells.
Phosphatidylserine and CD36 have particularly important roles in delivering
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immunosuppressive signals, as evidenced by the ability to mimic the inhibitory effects of
apoptotic cells with only phosphatidylserine-containing liposomes (85) or anti-CD36 (83).
In summary, ECP induces antigen-specific immunosuppression in GVHD (45) and
solid-organ transplant rejection (46, 47), and this immunomodulation is largely mediated
through the generation of antigen-specific Tregs (45-48). Moreover, both UV radiation
(1, 2) and apoptotic cells (74, 77-79) transmit immunosuppressive signals to DCs, and the
phenotypic and functional characteristics of tolerogenic DCs are essential for inducing
Tregs differentiation from naïve T-lymphocytes (41-43). Given this set of observations,
combined with the central role of GILZ in generating tolerogenic DCs (59) and Tregs
(69), we hypothesized that PUVA directly induces GILZ expression in immature DCs,
thereby polarizing them towards a tolerogenic phenotype and functional state. We
further hypothesized that the immunosuppressive signals delivered by lymphocytes,
rendered apoptotic by PUVA, induce GILZ expression in a similar fashion as
glucocorticoids, IL-10 and TGF-β. We developed a co-culture of human monocytederived DCs (MoDCs) and apoptotic lymphocytes (ApoL) as an in vitro model of ECP to
help decipher the direct and indirect immunosuppressive effects of PUVA.
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Hypotheses
Hypothesis A: PUVA directly induces GILZ expression in immature MoDCs in a dosedependent fashion and polarizes MoDCs towards a tolerogenic phenotype and function.
Hypothesis B: PUVA indirectly induces GILZ expression through the generation of
ApoL that are subsequently recognized by immature MoDCs. ApoL induce GILZ
expression in immature MoDCs, polarizing them towards a tolerogenic phenotype and
function.

Specific Aims
Specific Aim 1: To differentiate human monocytes into immature MoDCs in the
presence of GM-CSF and IL-4, and determine the dexamethasone dose-dependent
induction of GILZ to serve as a positive control.
Specific Aim 2: To quantify the susceptibilities of immature MoDCs and lymphocytes to
the apoptotic effects of PUVA.
Specific Aim 3: To determine if PUVA treatment and apoptotic cell exposure induces
GILZ expression in immature MoDCs.
Specific Aim 4: To characterize the phenotypic profile of MoDCs expressing GILZ at
high levels after PUVA treatment and/or apoptotic cell exposure, including expression of
the maturation marker CD83, and the co-stimulatory molecules CD80 and CD86.
Specific Aim 5: To characterize the functional profile of MoDCs expressing GILZ at
high levels after PUVA treatment and/or apoptotic cell exposure, including production of
IL-10 and various pro-inflammatory cytokines and chemokines, including IL-12.
Specific Aim 6: To establish if GILZ induction is responsible for the tolerogenic
cytokine profile observed after PUVA treatment and/or apoptotic cell exposure,
specifically in regards to the IL-10 to IL-12 ratio.
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Methods
3.1.

Authorship
JSF formulated the hypotheses regarding the induction of GILZ after exposure of

MoDCs to PUVA and apoptotic cells. JSF, in collaboration with RLE, RET and JC,
designed all experiments to provide laboratory support for these postulates. JSF
performed all of the methods, procedures and experiments described below. JSF, along
with RLE, RET and JC, analyzed and interpreted the data.

3.2. Sample Collection
Whole blood was acquired from healthy subjects under the guidelines of the Yale
Human Investigational Review Board, and informed consent was provided according to
the Declaration of Helsinki. Peripheral blood specimens were obtained by standard
venipuncture into syringes containing 0.1% heparin, and PBMC were isolated by
centrifugation over a Ficoll-Hypaque gradient (Isolymph, CTL Scientific, Deer Park,
NY). Cell viability was assessed by Trypan blue exclusion and PBMC were utilized
immediately after isolation.

3.3. Monocyte Enrichment
Freshly isolated PBMC were plated in 6-well polystyrene tissue culture plates at a
concentration of 5 x 106 cells/mL in RPMI-1640 (Gibco, Carlsbad, CA) supplemented
with 15% heat-inactivated human AB serum (Gemini, Sacramento, CA), L-glutamine,
and 25 mM HEPES. Monocytes were allowed to adhere to the plastic culture plate for 2
hr at 37oC and 5% CO2, after which non-adherent cells were removed, and adherent cells
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were vigorously washed with RPMI-1640 and incubated for an additional 1.5 hr at 37oC
and 5% CO2. Non-adherent cells were once again removed, and adherent cells were
vigorously washed as previously described. The purity of adherent and non-adherent
cells was determined by CD14 and CD3 flow cytometric staining (purity: 71.6 ± 5.6%
CD14+). Non-adherent cells (purity: 66.0 ± 4.5% CD3+) removed during plastic
adherence will now be referred to as lymphocytes.
Monocytes were also enriched from freshly isolated PBMC by negative selection
using the Monocyte Isolation Kit II (Miltenyi Biotec, Auburn, CA) according to the
manufacturer’s instructions, with the following modification: The purification buffer was
optimized to PBS supplemented with 2% autologous serum and 1 mM EDTA. Isolation
of unlabeled monocytes was achieved by negatively depleting the magnetically labeled
cells incubated with an antibody cocktail consisting of anti-human CD3, CD7, CD16,
CD19, CD56, CD123 and glycophorin A. The purity of enriched cells was determined
by CD14 flow cytometric staining (purity: 83.8 ± 3.8% CD14+).
Finally, monocytes were enriched from freshly isolated PBMC by CD14 positive
magnetic bead selection according to the manufacturer’s instructions (Miltenyi Biotec,
Auburn, CA), with the following modifications: 1.) The purification buffer was optimized
to PBS supplemented with 0.5% AB serum and 2 mM EDTA; 2.) 20 µL FcR blocker
(Miltenyi Biotec, Auburn, CA) was added to 107 cells and incubated for 10 min on ice;
3.) 2 µL anti-human CD14 -biotin labeled antibody (clone 61D3, eBioscience, San Diego,
CA) was then added to 107 cells and incubated for 20 min on ice; 4.) After washing with
purification buffer, 20 µL anti-biotin microbeads (Miltenyi Biotec, Auburn, CA) were
added to 107 cells and incubated for 15 min on ice. Cells were passed over a MACS
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separator column in a magnetic field (Miltenyi Biotec, Auburn, CA). Magnetically
labeled CD14+ monocytes were retained in the column, and the unlabeled cells were
washed off and saved. After removal of the column from the magnetic field,
magnetically labeled CD14+ monocytes were eluted as a positively selected fraction. The
purity of enriched cells was determined by CD14 flow cytometric staining (purity: 88.1 ±
3.5% CD14+).

3.4. Generation of Immature Monocyte-Derived DCs
Enriched monocytes were cultured at a density of 5 x 106 cells/mL in 6- and 12well polystyrene tissue culture plates at 37oC and 5% CO2 in RPMI-1640 supplemented
with heat-inactivated 15% human AB serum and 1% penicillin/streptomycin (now
referred to as complete media). 800 IU/mL recombinant human GM-CSF (R&D
Systems, Minneapolis, MN) and 1000 IU/mL recombinant human IL-4 (R&D Systems,
Minneapolis, MN) were added to cultures for 36 hr to induce monocyte to immature DC
differentiation as described (86). In comparative studies, MoDCs generated in 48 hr are
comparable with traditional MoDCs (87, 88) cultured for 5 days both phenotypically and
functionally (88, 89), and equally capable of eliciting T-lymphocyte responses in vitro
(86). After 36 hr, the immunophenotype of cells was analyzed to ensure that they
possessed an immature MoDC phenotype.

3.5. 8-MOP and UVA Light Treatment
Cultures were incubated with 20 µg/mL 8-MOP (Therakos, Raritan, NJ) for 30
min in the dark, and then irradiated with a desktop UVA light box containing a series of
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12 linear fluorescent tubes. Cells were washed once with PBS after treatment, and
replaced with fresh complete media. The tubes emitted UVA light ranging from 320 to
400 nm, with a peak emission of 365 nm. The UVA irradiance (power, W/m2) was
measured using a photodiode, removing visible light (>400 nm) with a low-pass filter.
The radiation emission of the lamp and the transmission characteristics of the media and
plastic plates used for cell culture were evaluated in order to determine their absorption
properties. Given a measured irradiance emitted from the fluorescent tubes, and the
absorption properties of the various components of the system, it was possible to
determine the time (sec) needed to expose the cells to deliver a given dose of UVA
radiation (J/cm2). A direct comparison between RPMI-1640 with or without phenol red
revealed no difference in the kinetics of lymphocyte apoptosis, and RPMI-1640 with
phenol red was chosen for all experiments involving 8-MOP and UVA light.

3.6. MoDC/Lymphocyte Co-Cultures
Cultures of MoDCs and lymphocytes were treated with PUVA independently.
Lymphocytes were treated with 8-MOP (100 ng/mL) and UVA light (1 J/cm2), washed
once with PBS, counted, and co-cultured with either PUVA-treated or untreated MoDCs
in a ratio of five or ten lymphocytes to one MoDC. PUVA-treated and untreated MoDCs
were also cultured alone, with no lymphocytes added. MoDCs treated for 24 hr with 100
nM dexamethasone (Sigma, Ronkonkoma, NY) were chosen as the positive control group
(59). All cells were cultured at 37oC and 5% CO2 in complete media. After 24 hr, cells
from all groups were harvested and MoDCs were re-purified. Given that lymphocytes
also express GILZ (60), it was critical to re-purify MoDCs from all cultures to ensure that

20
RNA was not isolated in significant quantity from lymphocytes. MoDCs were repurified using CD11c magnetic bead positive selection (purity: 96.4 ± 1.0% CD11c+, 3.2
± 1.1% CD3+ cell contamination) according to the manufacturer’s instructions (Miltenyi
Biotec, Auburn, CA). The CD11c positive magnetic bead selection was performed in an
identical fashion as previously described for the CD14 positive magnetic bead selection
of monocytes. CD11c+ MoDCs were then re-plated at 0.5 to 1.0 x 106 cells/mL in
complete media and stimulated with 100 ng/mL lipopolysaccharide (LPS, from E. coli
026:B6) (Sigma, Ronkonkoma, NY). 24 hr after LPS stimulation, cells were harvested
for RNA isolation and flow cytometric analysis, and supernatants were collected for
cytokine quantification. Parallel groups not receiving LPS were also analyzed.

3.7. siRNA-Mediated GILZ Knockdown
Silencer select pre-designed (inventoried) and validated GILZ siRNA (Invitrogen,
Carlsbad, CA; TSC22D3, sense: GCUUUGGGAUGACCGCUUAtt, antisense:
UAAGCGGUCAUCCCAAAGCtg), with off-target prediction algorithms, was used to
transiently knockdown GILZ expression in MoDCs. MoDCs were transfected using the
Lipofectamine RNAiMAX Reagent according to the manufacturer’s instructions
(Invitrogen, Carlsbad, CA). Opti-MEM I Reduced Serum Medium (Invitrogen, Carlsbad,
CA) was used to incubate diluted RNAi duplex and lipofectamine reagent for 20 min at
room temperature. RNAi duplex-lipofectamine complexes were then added to MoDC
cultures and incubated for 2 hr at 37oC and 5% CO2. Transfected MoDCs were treated in
an identical fashion as described for the MoDC/lymphocyte co-cultures. MoDCs were
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also transfected with scramble siRNA as a control. Each group contained a culture that
was not transfected. Transfection efficacy was determined by qRT-PCR.

3.8. Immunophenotyping
Monoclonal antibodies specific for monocytes and DCs included: HLA-DR FITC
(Beckman Coulter, Brea, CA; clone Immu-357), CD80 FITC (Beckman Coulter, Brea,
CA; clone MAB104), CD83 PE (Biolegend, San Diego, CA; clone HB15e), CD3 PE
(Biolegend, San Diego, CA; clone OKT3), CD86 PE (Biolegend, San Diego, CA; clone
IT2.2), GILZ PE (eBioscience, San Diego, CA; clone CFMKG15), CD14 PerCP/cy5.5
(eBioscience, San Diego, CA; clone 61D3), and CD11c APC (Biolegend, San Diego,
CA; clone 3.9). Antibodies were used at their pre-determined optimal dilutions and
staining was performed in the dark in FACS buffer (PBS plus 1% AB serum).
Apoptosis was assessed using the Annexin-V Apoptosis Detection Kit
(eBioscience, San Diego, CA), according to the manufacturer’s instructions, with 7-AAD
substituting for PI as the cell viability dye. Annexin-V binds phosphatidylserine on the
surface of apoptotic cells as the cell loses the ability to maintain membrane phospholipid
asymmetry (82). Phosphatidylserine exposure is the one of the earliest events that occurs
once a cell begins the process of apoptosis (82, 83). 7-AAD has a strong affinity for
nuclear DNA, and is an indicator of cell membrane integrity. When a cell is in a late
stage of apoptosis, or is undergoing secondary necrosis, the integrity of the cell
membrane may become compromised, and the cell’s DNA will stain with 7-AAD. Cells
displaying an Annexin-V+/7-AAD- phenotype were classified as early apoptotic cells, and
cells displaying an Annexin-V+/7-AAD+ phenotype were classified as late apoptotic cells.
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Dual membrane and intra-cytoplasmic staining was performed using the IntraPrep
fix and permeabilization kit (Beckman-Coulter, Brea, CA), according to the
manufacturer’s instructions. Intracytoplasmic staining was performed with GILZ and
CD83. Background staining was established with appropriate isotype and fluorescence
minus one controls. Immunofluorescence was analyzed using a FACSCalibur L (BD
Biosciences, San Jose, CA) within 2 hr of fixation with 2% paraformaldehyde. A
minimum of 10,000 events were collected for each group. Raw data was analyzed using
FlowJo software (TreeStar, Can Carlos, CA).

3.9. Quantitative Real-Time PCR
RNA was isolated from CD11c+ MoDCs using QIAShredder columns (QIAGEN,
Hilden, Germany) and the RNeasy Mini Kit (QIAGEN, Hilden, Germany), with oncolumn Dnase I treatment (QIAGEN, Hilden, Germany), according to the manufacturer’s
instructions. RNA yield and purity were assessed using a NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies, Wilmington, DE). The A260/280 ratio of
isolated RNA was consistently between 1.8 and 2.1, with RNA yields ranging from 100
ng to 5 µg. Up to 1 µg of RNA was immediately reverse transcribed to cDNA using the
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Middletown, CT)
according to the manufacturer’s instructions. Reverse transcription was performed in a
96-well thermocycler (MJ Research PTC-200, Waltham, MA), with the following run
conditions: 25o C (10 minutes), 37o C (120 minutes), 85o C (5 seconds). TaqMan realtime PCR was used to detect transcripts of GILZ, HPRT-1, CD80, and CD86. Primers
and probes were obtained as pre-designed and validated Taqman Gene Expression
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Assays (Applied Biosystems, Middletown, CT). SYBR green real-time PCR with Power
SYBR Green Master Mix (Applied Biosystems, Middletown, CT) was used to detect
transcripts of IL-12, IL-10, IL-6, TNF-α, TGF-β and GAPDH. Primers were designed to
span intron junctions using Primer3Plus and the CCDS consensus sequence for each
gene. Primer melting curves were obtained to confirm a single product and exclude
primer-dimer formation. HPRT-1 and GAPDH were used as reference genes. Samples
were run in triplicate on a 7500 Real Time PCR System (Applied Biosystems,
Middletown, CT), and raw data was analyzed using 7500 Software v.2.0.5. The deltadelta C(t) method was used to calculate the fold change relative to control cells. Primer
sequences are listed below for each gene.
IL-6 - PrimerF: GAGCTGTGCAGATGAGTACAAAA; PrimerR: GCATTTGTGGTTGGGTCAG
IL-10 - PrimerF: TCCCTGTGAAAACAAGAGCA; PrimerR: TGTCAAACTCACTCATGGCTTT
IL-12a - PrimerF: CAAGACCATGAATGCAAAGC; PrimerR: TCAAGGGAGGATTTTTGTGG
IL-12b - PrimerF: TGACATTCTGCGTTCAGGTC; PrimerR: CATTTTTGCGGCAGATGAC
TNF-α - PrimerF: GACAAGCCTGTAGCCCATGT; PrimerR: GAGGTACAGGCCCTCTGATG
TGF-β - PrimerF: GGCTTCTTGGTGCTGATGTC; PrimerR: TGCTTGGCAAACTCAGTGTC
GAPDH - PrimerF: CAATGACCCCTTCATTGACC; PrimerR: GACAAGCTTCCCGTTCTCAG

3.10. Cytokine Quantification
Culture supernatants were collected 24 hr after LPS stimulation, centrifuged at
1700 rpm for 10 min at 4oC to remove cells and debris, and immediately frozen at -80o C
for future cytokine and chemokine quantification. Supernatants were thawed on ice and
cytokine and chemokines were analyzed in a multiplex format utilizing magnetic beads to
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IL-6, IL-8, IL-10, IL-12p70, IFN-γ, TNF-α, RANTES, MCP-1, and MIP-1β (BioRad
Laboratories, Hercules, CA). For siRNA experiments, supernatants were analyzed with
enzyme-linked immunosorbent assay (ELISA) kits for IL-10 (R&D Systems,
Minneapolis, MD) and IL-12p70 (Enzo Life Science, Farmingdale, NY). All samples
and standards were run in duplicate and analyzed using the LUMINEX 200 (LUMINEX,
Austin TX), or the BioTek EL800 (BioTek, Winooski, VT).

3.11. Statistical Analysis
Student’s t-tests (paired and unpaired) were used for statistical comparisons
between groups, with p-values < 0.05 considered statistically significant. Differential
gene expression was considered statistically significant with a ≥ 2.5-fold change and a pvalue < 0.05.
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Results
4.1. Figure 1

Figure 1: GILZ expression was rapidly down-regulated as monocytes differentiated
into immature MoDCs, and up-regulated after exposure to dexamethasone.
Total RNA was isolated from MoDCs. A.) GILZ mRNA expression in CD11c+ MoDCs
is presented as a fold change relative to freshly isolated monocytes. B.) Median
fluorescence intensities for intracellular markers (GILZ, CD83) and cell surface markers
(CD11c, CD14, CD83) in CD11c+-gated MoDCs after 36 hr of culture with GM-CSF and
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IL-4. C.) GILZ mRNA expression in CD11c+ MoDCs after 24 hr is presented as a fold
change relative to MoDCs receiving no dexamethasone. D.) GILZ mRNA expression in
CD11c+ MoDCs after 24 hr is presented as a fold change relative to untreated MoDCs.
E.) GILZ mRNA expression in CD11c+ MoDCs is presented as a fold change relative to
untreated MoDCs. All data are expressed as mean ± standard deviation for a minimum of
3 independent experiments. For differential gene expression, a ≥ 2.5-fold change was
chosen as the lower limit for considering statistically significant gene induction. *p <
0.05, **p < 0.01, ***p < 0.001, compared to the untreated MoDC group.

GILZ expression was rapidly down-regulated as monocytes differentiated into
immature MoDCs
Freshly isolated CD14+ monocytes expressed GILZ at high levels, but rapidly
down-regulated GILZ expression by more than 99% as they differentiated into immature
MoDCs in the presence of GM-CSF and IL-4 (Figure 1A, p < 0.001). Expression of
GILZ remained low in immature MoDCs for at least 72 hr in culture with no additional
cytokines added. The reduction in GILZ mRNA was confirmed by a 61% decrease in
intracellular GILZ protein level, as assessed by flow cytometric staining (Figure 1B, p <
0.01). Down-regulation of GILZ mRNA and protein level was correlated with reduced
expression of CD14, a monocyte-specific marker (89) (Figure 1B, p < 0.01), and
increased expression of cytoplasmic CD83, a marker of immature MoDCs (90) (Figure
1B, p < 0.01). HLA-DR expression also increased after 36 hr of culture, with the median
fluorescent intensity (MFI) increasing from 22.8 to 149.7 (p < 0.01), and the percentage
of CD11c+ cells displaying a HLA-DR+/cytoplasmic CD83+ phenotype increasing from
15.0 ± 11.6% to 90.8 ± 5.5% (p < 0.01). Importantly, MoDCs remained phenotypically
immature after 36 hr of culture, with a statistically insignificant change in expression of
membrane CD83, a marker of mature MoDCs (90) (Figure 1B, p = 0.16).
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As previously reported (59), dexamethasone induced the expression of GILZ in
immature MoDCs in a dose-dependent fashion, starting at a dexamethasone concentration
of 10 nM (Figure 1C, p < 0.05). Treatment with 100 nM dexamethasone for 24 hr was
selected as the positive control for inducing GILZ expression in MoDCs for all future
experiments (now referred to as Dex-DCs). In addition, after a single dose of 100 nM
dexamethasone, GILZ was up-regulated 3.9-fold above untreated MoDCs for at least 72
hr in culture, reflecting temporal stability of GILZ up-regulation (Figure 1F, p < 0.05).
This observation enabled further experiments to operate on 48 hr time scales with a single
administration of dexamethasone at the initiation of cell culture.
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4.2. Figure 2

Figure 2: Immature MoDCs treated with 8-MOP plus UVA light up-regulated
GILZ in a dose-dependent fashion and acquired a tolerogenic phenotype.
Total RNA was isolated from MoDCs treated with PUVA. A.) GILZ mRNA expression
is presented as a function of the 8-MOP concentration at UVA light doses of 1 J/cm2 and
2 J/cm2. GILZ mRNA expression in CD11c+ MoDCs 24 hr after PUVA treatment is
presented as a fold change relative to MoDCs receiving no 8-MOP. B.) GILZ mRNA
expression is presented as a function of the 8-MOP concentration multiplied by the UVA
light dose. GILZ mRNA expression in CD11c+ MoDCs 24 hr after PUVA treatment is
presented as a fold change relative to MoDCs receiving no PUVA. Relative fluorescence
intensities for membrane expression of C.) HLA-DR and CD83, and D.) CD80 and
CD86, are presented as a function of the 8-MOP concentration (0 to 200 ng/mL)
multiplied by the UVA light dose (1 or 2 J/cm2), 24 hr after PUVA treatment in CD11c+gated MoDCs. Untreated MoDCs served as reference controls. All data represent mean
± standard deviation for at least 4 independent experiments. For differential gene
expression, a ≥ 2.5-fold change was chosen as the lower limit for considering statistically
significant gene induction. *p < 0.05, **p < 0.01, compared to the untreated MoDC
group.
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4.3. Table 1

Table 1: 8-MOP plus UVA light induced a tolerogenic phenotype in immature
MoDCs in a PUVA dose-dependent fashion.
Individual relative fluorescence intensities for membrane expression of CD80, CD86,
CD83 and HLA-DR are presented as a function of the 8-MOP concentration (0 to 200
ng/mL) at both 1 and 2 J/cm2 UVA light in CD11c+-gated MoDCs. Untreated MoDCs
served as reference controls. All data represent mean ± standard deviation for at least 4
independent experiments. Boxes shaded in dark grey indicate statistically significant
changes from untreated MoDCs, with p < 0.05.

The combination of 8-MOP and UVA light directly induced GILZ expression and
established a tolerogenic phenotype in MoDCs
We next examined if PUVA has a direct effect on GILZ expression in immature
MoDCs. Treatment with 100 ng/mL 8-MOP or 1 J/cm2 UVA light alone did not
significantly change GILZ expression (Figure 1E, p > 0.05). However, when MoDCs
were treated with the combination of 100 ng/mL 8-MOP and 1 J/cm2 UVA light (now
referred to as PUVA-DCs), GILZ expression increased 5.5-fold in comparison to MoDCs
receiving no PUVA treatment (Figure 1E, p < 0.05). The induction of GILZ in PUVADCs exhibited a slower time course in comparison to Dex-DCs, peaking 24 hr after
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treatment with a 4.3-fold change above untreated MoDCs, and remaining significantly
elevated, above a 3-fold change, for 72 hr in culture (Figure 1F, p < 0.05). In contrast,
the induction of GILZ in Dex-DCs peaked in as little as 2 hr after dexamethasone
treatment with an 8.7-fold change above untreated MoDCs, and remained significantly
elevated for 72 hr in culture (Figure 1F, p < 0.05). The percentage of apoptotic cells did
not differ after treatment with 100 ng/mL 8-MOP or 1 J/cm2 UVA light, as compared to
untreated MoDCs (data not shown). There was also no significant difference in the total
number of cells recovered from any group, and greater than 90% of CD11c+ MoDCs
remained viable 24 hr after treatment with 100 ng/mL 8-MOP, 1 J/cm2 UVA light, or the
combination of both (data not shown).
After establishing that PUVA induces GILZ expression, we examined if there was
an 8-MOP or UVA light dose-dependent effect on GILZ induction. MoDCs treated with
1 J/cm2 UVA light up-regulated GILZ 2.9- and 4.4-fold higher than untreated MoDCs as
the 8-MOP concentration reached therapeutic doses of 100 and 200 ng/mL respectively
(Figure 2A, p < 0.01). A similar dose-dependent phenomenon was observed with 2
J/cm2 UVA light, starting at a lower 8-MOP dose of 50 ng/mL (Figure 2A, p < 0.01).
In vivo studies utilizing highly specific 8-MOP photo-adduct monoclonal
antibodies in human lymphocytes revealed that the number of photo-adducts formed per
one million base pairs is directly proportional to the product of the 8-MOP concentration
and UVA light dose (91). When examining GILZ expression as a function of the 8-MOP
and UVA light product, a similar dose-dependent effect was observed. GILZ was upregulated 3-fold above untreated MoDCs as the product of 8-MOP and UVA light
reached 100, and 4.8- and 8.6-fold as the product increased to 200 and 400 respectively
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(Figure 2B, p < 0.01). Treatment with 0.5 J/cm2 UVA light had no significant effect on
GILZ expression until the 8-MOP dose was greater than 200 ng/mL (data not shown).
Treatment with 4 J/cm2 UVA light resulted in high levels of non-specific cell death posttreatment, and the effects of this higher UVA light dose on GILZ expression could not be
reliably determined (data not shown).
In dexamethasone-treated cultures, expression of GILZ truncates DC maturation
and mediates the conversion to a tolerogenic phenotype (92). In a similar fashion, the
PUVA dose-dependent induction of GILZ was correlated with decreased cell surface
expression of the maturation marker membrane CD83 (Figure 2C, p < 0.01), and the costimulatory molecules CD80 and CD86 (Figure 2D, p < 0.01), in CD11c+-gated MoDCs.
Down-regulation of these markers paralleled the induction of GILZ (see Figure 2B),
beginning at an 8-MOP concentration of 100 ng/mL for UVA light doses of 1 and 2
J/cm2. As the product of 8-MOP and UVA light exceeded 100, the expression of CD83,
CD80 and CD86 were reduced by 31%, 30% and 54% respectively (Figure 2C, 2D, p <
0.01), and the expression of HLA-DR was increased by 38% (Figure 2C, 2D, p < 0.05).
These same trends were observed when examining the relative fluorescence
intensities (RFIs) for each cell surface marker, at each particular dose of 8-MOP and
UVA light in CD11c+-gated MoDCs. As the 8-MOP concentration increased at both 1
and 2 J/cm2 UVA light, the RFIs for CD80, CD86 and CD83 all steadily decreased, in a
similar fashion as Dex-DCs (Table 1, p < 0.05). Although the expression of HLA-DR
increased at 100 ng/mL 8-MOP for both 1 and 2 J/cm2 UVA light, it dropped
precipitously at a dose of 200 ng/mL 8-MOP and 2 J/cm2 UVA light (Table 1, p < 0.05).
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Greater than 90% (range 91.0-97.5%) of CD11c+ MoDCs were harvested from all
cultures after treatment with the range of PUVA doses tested.
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4.4. Figure 3

Figure 3: MoDCs were relatively resistant to the apoptotic effects of 8-MOP plus
UVA light.
A.) Flow cytometry dot plots of CD11c+-gated MoDCs treated with UVA light doses of 1
J/cm2 or 2 J/cm2, and increasing concentrations of 8-MOP, are shown for 1 representative
experiment of 4. The percentages of CD11c+ cells displaying Annexin-V+/7-AAD- (early
apoptotic) or Annexin-V+/7-AAD+ (late apoptotic) phenotypes are indicated. The
percentages of B.) Annexin-V+/7-AAD- (early apoptotic) and C.) Annexin-V+/7-AAD+
(late apoptotic) phenotypes are quantified and presented as a function of the 8-MOP
concentration and UVA dose. Untreated cells served as reference controls. All data
represent mean ± standard deviation for at least 4 independent experiments. *p < 0.05,
compared to the untreated MoDC group.
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4.5. Figure 4

Figure 4: MoDCs and lymphocytes differed in their susceptibility to the apoptotic
effects of 8-MOP plus UVA light.
A.) Flow cytometry dot plots of CD11c+-gated MoDCs and CD3+-gated lymphocytes
treated with a UVA light dose of 1 J/cm2, and increasing concentrations of 8-MOP, are
shown for 1 representative experiment of 3. The percentages of CD11c+ MoDCs
displaying an Annexin-V+/7-AAD- (early apoptotic) or Annexin-V+/7-AAD+ (late
apoptotic) phenotype are indicated at 0, 2, 8 and 24 hr. The percentages of B.) CD11c+
MoDCs and C.) CD3+ lymphocytes expressing early and late apoptotic cell markers were
quantified 24 hr after treatment with 100 ng/mL 8-MOP and 1 J/cm2 UVA light.
Untreated MoDCs and lymphocytes served as reference controls. All data represent
mean ± standard deviation for at least 3 independent experiments. *p < 0.05, compared
to the untreated MoDC or lymphocyte group.

35
Lymphocytes were particularly susceptible, whereas MoDCs were relatively
resistant, to the apoptotic effects of PUVA
There is a lack of consensus in the literature regarding the apoptotic effects of
PUVA treatment on monocytes and DCs, with studies showing both a resistance (12, 2123), and sensitivity (24-26), to apoptosis. The relative resistance of MoDCs to the
apoptotic effects of PUVA can be directly observed on flow cytometry dot plots from 1
representative experiment of 4 (Figure 3A). The percentage of early apoptotic (AnnexinV+/7-AAD-) CD11c+-gated MoDCs was minimally higher when treated with 2 J/cm2 as
compared to 1 J/cm2 UVA light, across the range of 8-MOP concentrations tested (0 to
200 ng/mL) (Figure 3A, p > 0.05). Of note, there was a statistically significant increase
in the percentage of early apoptotic CD11c+-gated MoDCs when treated with 2 J/cm2
UVA light and 200 ng/mL 8-MOP, as compared to untreated MoDCs (Figure 3A, 3B, p
< 0.05). Nevertheless, apart from this isolated PUVA dose, the percentage of early
apoptotic MoDCs remained below 25% (range 3.4-20.2%) over the range of 8-MOP and
UVA light doses examined (Figure 3B, p > 0.05).
The percentage of late apoptotic (Annexin-V+/7-AAD+) CD11c+-gated MoDCs
also remained low (range 6.3-15.2%), and statistically not different than untreated
MoDCs, at both 1 J/cm2 and 2 J/cm2 UVA light for all concentrations of 8-MOP tested
(Figure 3C, p > 0.05). Moreover, greater than 90% CD11c+ MoDCs (range 91.0-97.5%)
were harvested after PUVA treatment from all groups treated with 1 or 2 J/cm2 UVA
light.
In comparison to MoDCs, CD3+-gated lymphocytes displayed phosphatidylserine
on their cell surface as early as 2 hr after treatment with 1 J/cm2 UVA light and 100
ng/mL 8-MOP (Figure 4A). As directly observed on flow cytometry dot plots from 1

36
representative experiment of 3, 2 hr after treatment with 1 J/cm2 UVA light and 100
ng/mL 8-MOP, the percentage of early apoptotic CD3+-gated lymphocytes increased
from 7.5% to 21.1% (Figure 4A). Moreover, the percentage of early and late apoptotic
CD3+-gated lymphocytes further increased at both 8 and 24 hr (Figure 4A). In
comparison, there was no significant increase in the percentage of early or late apoptotic
CD11c+-gated MoDCs after treatment with the same dose of 8-MOP and UVA light at 2,
8 or 24 hr (Figure 4A).
Figures 4B and 4C quantify the striking difference in susceptibility of MoDCs and
lymphocytes to an identical 8-MOP and UVA light dose. While there were no
differences observed in the percentages of early or late apoptotic CD11c+-gated MoDCs
24 hr after treatment with 100 ng/mL 8-MOP and 1 J/cm2 UVA light (Figure 4B, p >
0.05), there was a large increase in the percentage of early and late apoptotic lymphocytes
24 hr after PUVA treatment (Figure 4C, p < 0.05). The percentage of early apoptotic
lymphocytes increased from 6.6% in untreated lymphocytes to 44.3% in PUVA-treated
lymphocytes, and the percentage of late apoptotic lymphocytes increased from 4.5% to
33.7% (Figure 4C, p < 0.05). Given that 64.3 ± 3.2% (p < 0.001) of CD3+-gated
lymphocytes displayed phosphatidylserine on their cell surface and were apoptotic 24 hr
after PUVA treatment, PUVA-treated lymphocytes are subsequently referred to as
apoptotic lymphocytes (ApoL).
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4.6. Figure 5

Figure 5: Immature MoDCs exposed to apoptotic lymphocytes up-regulated GILZ
and were resistant to full maturation with LPS.
A.) GILZ mRNA expression in CD11c+ MoDCs 24 hr after co-culture is presented as a
fold change relative to untreated MoDCs that were cultured alone. MoDCs were cocultured in ratios of five and ten apoptotic lymphocytes to one untreated MoDC. B.)
GILZ mRNA expression in CD11c+ MoDCs 24 hr after co-culture is presented as a fold
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change relative to untreated MoDCs that were cultured alone. C.) Relative fluorescence
intensity of GILZ 24 hr after co-culture. Relative fluorescence intensities post- to preLPS stimulation for D.) CD80 and CD86, and E.) HLA-DR and CD83, were calculated
as follows: (MFItreated after LPS – MFItreated before LPS) / (MFIuntreated after LPS – MFIuntreated before
LPS). Data represent mean ± standard deviation for at least 4 independent experiments.
For differential gene expression, a ≥ 2.5-fold change was chosen as the lower limit for
considering statistically significant gene induction. *p < 0.05, **p < 0.01, ***p < 0.001,
compared to the untreated MoDC group, unless noted otherwise.
MoDCs exposed to apoptotic lymphocytes increased expression of GILZ and were
resistant to full maturation after LPS stimulation
To dissect the direct effects of PUVA on MoDCs, and the indirect effects of
PUVA through the generation of ApoL, immature MoDCs were co-cultured for 24 hr
with increasing numbers of ApoL. Exposure of MoDCs to ApoL induced GILZ
expression in an ApoL dose-dependent fashion, with GILZ expressed higher in MoDCs
co-cultured in a ten to one ratio of ApoL to MoDCs as compared to a five to one ratio
(4.4-fold compared to 2.8-fold higher than untreated MoDCs, respectively) (Figure 5A, p
< 0.01). As a positive control, dexamethasone induced GILZ expression 4.2-fold above
untreated MoDCs in this particular set of experiments (Figure 5A, p < 0.01).
In addition, PUVA-DCs co-cultured with ApoL expressed GILZ at higher levels
than PUVA-DCs cultured alone (6.7-fold compared to 2.8-fold higher than untreated
MoDCs, respectively) (Figure 5B, p < 0.05). PUVA-DCs exposed to ApoL also
expressed GILZ at higher levels than did untreated MoDCs exposed to ApoL (6.7-fold
compared to 3.6-fold higher than untreated MoDCs, respectively) (Figure 5B, p < 0.01).
Increased GILZ mRNA production was associated with at least a 1.5-fold increase (range
1.56-2.23) in the intracellular level of GILZ protein (Figure 5C, p < 0.001). The
induction of GILZ was not related to an increase in the number of early or late apoptotic
cells, as there were less than 12% early apoptotic (range 3.8-11.4%) and 12% late
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apoptotic (range 6.3-11.5%) CD11c+ MoDCs in all groups demonstrating induction of
GILZ (p > 0.05, as compared to untreated MoDCs).
Immature MoDCs exposed to LPS rapidly mature and increase membrane
expression of HLA-DR, CD83, CD80 and CD86 (93). MoDCs expressing GILZ greater
than 2.5-fold above untreated MoDCs were resistant to full maturation by the TLR4
ligand LPS, and acquired a semi-mature, tolerogenic phenotype. LPS stimulation
increased CD80 expression in MoDCs up-regulating GILZ to only 50% (range 48-57%)
of the levels seen after LPS stimulation in untreated MoDCs (Figure 5D, p < 0.05), and
LPS stimulation increased CD86 expression to only 45% (range 42-47%) of untreated
MoDCs (Figure 5D, p < 0.01). Similar results were obtained for CD83 (range 47-65%)
and HLA-DR (range 23-57%), as compared to untreated MoDCs after LPS stimulation
(Figure 5E, p < 0.05). The reduction in cell surface marker expression was confirmed at
the mRNA level for CD80 and CD86, as assessed by qRT-PCR. MoDCs up-regulating
GILZ expressed 6% of the CD80 mRNA transcript level of untreated MoDCs (range 4.57.5%, p < 0.05) and expressed 50% of the CD86 mRNA transcript level of untreated
MoDCs (range 12.4-85.1%, p < 0.05). MoDCs not stimulated with LPS served as
negative controls, and demonstrated baseline expression levels for all cell surface
markers, and also had low transcript levels for both CD80 and CD86 mRNA (data not
shown).
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4.7. Figure 6

Figure 6: MoDCs up-regulating GILZ at high levels increased IL-10 production,
and decreased production of various pro-inflammatory cytokines and chemokines.
MoDCs from cultures described in Figure 5 were stimulated with LPS, and after 24 hr
culture supernatants were harvested for cytokine quantification by magnetic bead
multiplex immunoassays for A.) IL-10, and the pro-inflammatory cytokines B.) IL-12p70
and IFN-γ, and C.) IL-6 and TNF-α. The same analysis was performed for the proinflammatory chemokines D.) IL-8, and E.) MCP-1, MIP-1β and RANTES. Data are
presented as mean ± standard deviation for 3 independent experiments. *p < 0.05
compared to the untreated MoDC group.
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4.8. Figure 7

Figure 7: siRNA-mediated knockdown of GILZ abolished the tolerogenic cytokine
profile, as evidenced by reduced IL-10 production and increased IL-12 production.
MoDCs were transfected with GILZ or scramble siRNA, and cultured as described in
Figure 5. A.) GILZ mRNA expression in CD11c+ MoDCs transfected with GILZ or
scramble siRNA is presented as a fold change compared to non-transfected, untreated
MoDCs that were cultured alone. * ≥ 2.5-fold change and p < 0.05, compared to
identically treated MoDCs not transfected with siRNA. Quantification of B.) IL-10 and
C.) IL-12p70 protein levels in culture supernatants 24 hr after LPS stimulation. Data
represent mean ± standard deviation for 3 independent experiments. *p < 0.05, compared
to identically treated MoDCs not transfected with siRNA.

42
4.9. Table 2

Table 2: MoDCs expressing GILZ at high levels demonstrated an increased IL-10
to IL-12 ratio characteristic of tolerogenic DCs, and siRNA-mediated knockdown of
GILZ reduced the IL-10 to IL-12 ratio.
GILZ mRNA expression in CD11c+ MoDCs is presented as a fold change relative to
untreated MoDCs that were cultured alone. Individual IL-10 and IL-12 levels are
presented, with a calculation of the IL-10 to IL-12 ratio for each group. Data represent
mean ± standard deviation for 3 independent experiments. Shaded boxes highlight the
IL-10 to IL-12 ratio for each group.

MoDCs expressing high levels of GILZ displayed a tolerogenic cytokine profile, and
siRNA-mediated knockdown of GILZ reduced the IL-10 to IL-12 ratio
Tolerogenic DCs are characterized by increased production of
immunosuppressive cytokines and decreased production of pro-inflammatory cytokines
and chemokines (36, 40-42). To analyze the functionality of MoDCs expressing GILZ at
high levels, supernatants were harvested from the co-cultures described in Figure 5B.
Dex-DCs expressed GILZ 4.29-fold above untreated MoDCs (see Figure 5B, p < 0.01),
and in comparison to untreated MoDCs, increased production of the immunosuppressive
cytokine IL-10 (Figure 6A, p < 0.05). In addition, Dex-DCs decreased production of the
pro-inflammatory cytokines IL-12p70 and IFN-γ (Figure 6B, p < 0.05), IL-6 and TNF-α
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(Figure 6C, p < 0.05), and chemokines IL-8 (Figure 6D, p < 0.05), and MCP-1 and
RANTES (Figure 6E, p < 0.05). Dex-DCs did not, however, significantly decrease
production of the chemokine MIP-1β (Figure 6E, p > 0.05).
PUVA-DCs expressed GILZ 2.78-fold above untreated MoDCs (see Figure 5B, p
< 0.01), and in comparison to untreated MoDCs, increased production of IL-10 (Figure
6A, p < 0.05). PUVA-DCs also decreased production of IL-12p70, IL-6, IL-8, MCP-1,
MIP-1β and RANTES (Figure 6B-6E, p < 0.05), but not TNF-α or IFN-γ (Figure 6B,
6C, p > 0.05). As previously noted, both PUVA-DCs and untreated MoDCs, when cocultured with ApoL, expressed GILZ at higher levels that PUVA-DCs cultured alone
(3.6- and 6.7-fold higher, respectively) (see Figure 5B, p < 0.01). In comparison to
untreated MoDCs, these two groups both increased production of IL-10 (Figure 6A, p <
0.05), and decreased production of the pro-inflammatory cytokines IL-12p70, IFN-γ, IL-6
and TNF-α (Figure 6B, 6C, p < 0.05) and chemokines IL-8, MCP-1, MIP-1β and
RANTES (Figure 6D, 6E, p < 0.05).
Cytokine levels were also analyzed at the RNA level for IL-10, IL-12, TNF-α and
TGF-β, as assessed by qRT-PCR. MoDCs that significantly up-regulated GILZ 2.5-fold
above untreated MoDCs also up-regulated IL-10 mRNA transcripts to levels 8-fold
greater than untreated MoDCs (range 5.5-11.8 fold higher, p < 0.01). Moreover, these
MoDCs down-regulated IL-12 mRNA transcripts to levels 1.7-fold lower than MoDCs
(range 1.1-3.2 fold lower, p < 0.05), and down-regulated TNF-α mRNA transcripts to
levels 1.4-fold lower than MoDCs (range 1.1-2.0 fold lower, p > 0.05). In addition, TGFβ mRNA was up-regulated in PUVA-DCs 3.4-fold above untreated MoDCs (range 2.24.6 fold higher, p < 0.05), and in PUVA-DCs exposed to ApoL, TGF-β mRNA was up-
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regulated 3.0-fold above untreated MoDCs (range 2.9-3.0 fold higher, p < 0.05). In
untreated MoDCs exposed to ApoL, TGF-β was marginally up-regulated only 2.1-fold
above untreated MoDCs (range 1.2-3.0 fold higher, p > 0.05), and TGF-β mRNA
transcripts were actually lower in Dex-DCs (0.8-fold lower in comparison to untreated
MoDCs) (range 0.8-0.9 fold lower, p > 0.05). Of note, TGF-β was not included in the
multiplex cytokine analysis and therefore was only analyzed at the mRNA level.
To assess whether the induction of GILZ was mediating the observed tolerogenic
cytokine profile, MoDCs were transfected with GILZ specific-siRNA to transiently
knockdown GILZ expression. Transfection with GILZ siRNA reduced GILZ expression
in MoDCs by 65% (range 57-69%, of non-transfected MoDCs) (Figure 7A, p < 0.05).
Transfection with scramble siRNA did not significantly change GILZ expression (range
86-112% of non-transfected MoDCs) (Figure 7A, p > 0.05). There was no significant
difference in the number of cells recovered from any group transfected with siRNA as
compared to non-transfected groups (data not shown, p > 0.05). MoDCs up-regulating
GILZ 2.5-fold higher than untreated MoDCs, in both the non-transfected and scramble
siRNA groups, produced higher levels of IL-10 (Figure 7B, p < 0.05). Transient
knockdown of GILZ reduced IL-10 production by 39% (range 34-48%) (Figure 7B, p <
0.05). MoDCs up-regulating GILZ 2.5-fold higher than untreated MoDCs in both the
non-transfected and scramble siRNA groups also produced lower levels of IL-12p70
(Figure 7C, p < 0.05). Transient knockdown of GILZ increased IL-12p70 production by
188% (range 149-214%) (Figure 7C, p < 0.05). Treatment with scramble siRNA had no
appreciable effect on the production of either IL-10 or IL-12p70 (Figure 7B, 7C, p >
0.05).
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The ratio of IL-10 to IL-12 production is a useful indicator of tolerogenicity, and
tolerogenic DCs are characterized by an increased IL-10 to IL-12 ratio (36, 40-42). The
IL-10 to IL-12 ratio increased from 5.0 in untreated MoDCs to 15.3 in Dex-DCs (Table
2). Similarly, the IL-10 to IL-12 ratio increased to 8.4 in PUVA-DCs, increased to 18.1
in untreated MoDCs exposed to ApoL, and increased to 28.4 in PUVA-DCs exposed to
ApoL (Table 2).
Transient knockdown of GILZ with siRNA reduced the IL-10 to IL-12 ratio that
had been elevated following GILZ induction. The IL-10 to IL-12 ratio decreased from
15.3 to 3.9 in siRNA transfected Dex-DCs (Table 2). Similarly, in siRNA transfected
PUVA-DCs, the ratio decreased from 8.4 to 2.9, in siRNA transfected untreated MoDCs
exposed to ApoL, the ratio decreased from 18.1 to 7.8, and finally in siRNA transfected
PUVA-DCs exposed to ApoL, the ratio decreased from 28.4 to 8.3 (Table 2, p < 0.05).

46

Discussion
5.1. Summary of Results
This study demonstrates that PUVA acts directly on MoDCs, and indirectly
through the generation of ApoL, to induce expression of GILZ. MoDCs up-regulating
GILZ displayed a tolerogenic phenotype, characterized by moderate expression of the
MHC-class II molecule HLA-DR, low expression of the co-stimulatory molecules CD80
and CD86, and low expression of the maturation marker CD83. Moreover, MoDCs upregulating GILZ were resistant to full maturation by the TLR4 ligand LPS, indicating that
they were in a tolerogenic, semi-mature state, unable to mature and respond to classic
immunogenic stimuli.
In addition, MoDCs treated with PUVA, or exposed to lymphocytes rendered
apoptotic by PUVA, were polarized towards a tolerogenic cytokine profile, characterized
by increased IL-10 production and decreased production of pro-inflammatory cytokines,
including IL-12, IFN-γ, IL-6 and TNF-α, and chemokines, including IL-8, MCP-1, MIP1β, and RANTES. GILZ was necessary for the conversion to this tolerogenic cytokine
profile, as demonstrated by a reduction in the IL-10 to IL-12 ratio after siRNA-mediated
transient knockdown of GILZ. PUVA and apoptotic cells can now be included in the list
of immunosuppressive stimuli - including glucocorticoids, IL-10 and TGF-β - all sharing
GILZ induction as the common downstream mechanism mediating their tolerogenic
effects.
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5.2. Direct Effects of PUVA
The molecular pathways mediating PUVA’s direct induction of GILZ are
presently unknown, but may be related to DNA damage, protein modifications, or
cellular stress. IL-10 levels were also elevated in PUVA-treated cultures, indicating that
autocrine or paracrine IL-10 signaling could have been the primary event inducing GILZ
expression (73). However, this is less likely given that the measured IL-10 concentration
was 350 times lower than that used to induce moderate GILZ expression in prior studies
(59).
While 8-MOP is biologically inert in the absence of UVA light energy, UV
radiation is immunosuppressive (1, 3), and activates numerous transcription factors,
including the immediate early genes c-fos, c-jun, and c-myc (94) . Moreover,
transcription factor induction is observed even in DNA repair-deficient cells (94),
indicating that photo-adduct repair and processing are not required for gene induction.
PUVA itself also alters gene expression in mouse keratinocytes (95), and generates bulky
DNA-protein cross-links (96), reactive oxygen species (97, 98), and lipid modifications
(99, 100), all of which may be able to induce gene expression. Given the relative
resistance of MoDCs to apoptosis, sub-lethal DNA damage and generalized cellular stress
may be capable of inducing GILZ and generating tolerogenic DCs. Interestingly, IL-2
growth factor deprivation induces GILZ expression in T-lymphocytes and protects them
from IL-2 withdrawal-induced apoptosis (101). PUVA may induce GILZ expression in a
similar fashion, protecting MoDCs from PUVA-induced apoptosis.
Multiple studies link cellular stress with GILZ induction. Firstly, rat
macrophages subjected to hypoxic conditions up-regulate GILZ in an ERK-dependent
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fashion (102). Secondly, caspase-8, linked to the immediate pre-programmed apoptotic
pathway induced by PUVA (16, 17), protects GILZ from degradation by facilitating its
binding to the small ubiquitin-like modifier 1 (SUMO-1) (103). SUMO-1 is covalently
attached to proteins during post-translational modifications, and is involved in many
cellular processes, including apoptosis and the response to stress (103). The presence of
SUMO binding sites on the GILZ protein suggests a close relationship between GILZ
induction, cellular stress and apoptosis (103). Thirdly, a recent report suggested that
treatment of mouse bone marrow derived DCs with thermal stress in the presence of
carvacrol, a molecule with anti-inflammatory properties, could induce functionally
tolerogenic DCs (104). Fourthly, GILZ has even been shown to be an alcohol-responsive
gene, becoming up-regulated in response to ethanol in a dose-dependent manner (105).
Finally, exposure to certain microbial products, including C. difficile toxin B and Y.
enterocolitica virulence factor YopT, induce GILZ expression (106). The notion that
cellular stress may induce a default tolerogenic pathway of DC differentiation has not
been systematically explored to date. However, given the importance of maintaining
peripheral tolerance to self-antigens exposed during tissue damage in times of
inflammation and infection (34-36), the idea that a tolerogenic differentiation program
may become activated in a subset of DCs during stressful environmental conditions
warrants further investigation.
The product of the 8-MOP and UVA light dose is directly proportional to the
number of photo-adducts formed per one million base pairs (91). A direct role for protein
and/or DNA photo-adduct formation contributing towards GILZ induction is supported
by the 8-MOP and UVA light product dose-dependent up-regulation of GILZ (see Figure
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2B). It is interesting to note that the induction of GILZ, and down-regulation of CD80,
CD86 and CD83, only occurred as the product of 8-MOP and UVA light reached
therapeutic levels, namely between 100 and 200 (see Figure 2C, 2D). Doses of 8-MOP
and UVA light used during ECP vary between treatment centers, but generally range
from 1 to 2 J/cm2 of UVA light and from 100 to 200 ng/mL of 8-MOP (7-10). Downregulation of these markers was likely not due to the non-specific global suppression of
all cell surface marker expression, as the expression level of HLA-DR increased at
identical PUVA doses. In support of these data, a prior study also noted increased
antigen uptake and HLA-DR expression in PUVA-treated MoDCs (53), and also
enhanced MHC class I synthesis after low-dose PUVA treatment (98).

5.3. Apoptotic Effects of PUVA
In support of previously published studies (12, 21-23), MoDCs were relatively
resistant to the apoptotic effects of PUVA. The discrepancy between these data, and
other reports suggesting a susceptibility of MoDCs to apoptosis (24-26), may stem from
variations in the PUVA dose used for treatment. For example, Holtick et al. reported a
susceptibility of MoDC to apoptosis, but utilized both a high 8-MOP concentration (300
ng/mL) and UVA light dose (2 J/cm2) (25). This 8-MOP and UVA light product,
proportional to the extent of DNA damage, is approximately twice the therapeutic dose
(7, 25). Likewise, Yoo et al. reported that MoDC apoptosis was observed with 8-MOP
administration alone, at doses greater than 300 ng/mL (13), and with UVA light alone, at
doses greater than 2 J/cm2 (13), suggesting that very high doses of either 8-MOP or UVA
light alone can also lead to non-specific cell death.
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In this present study, high doses of PUVA only minimally increased the
percentage of early apoptotic MoDCs. However, after treatment with a supra-therapeutic
dose (2 J/cm2 UVA light and 200 ng/mL 8-MOP), the percentage of early apoptotic
MoDCs significantly increased (see Figure 3). The transcriptional and phenotypic
changes observed at this high PUVA dose were likely non-specific, given a marked
decrease in the RFIs for all cell surface markers, including HLA-DR (see table 1).
Importantly though, no therapeutic PUVA dose used in this study increased the
percentage of late apoptotic MoDCs above the levels observed with untreated MoDCs,
indicating that rapid MoDC death is likely not occurring during or after ECP.
The previously documented exquisite sensitivity of lymphocytes to the apoptotic
effects of PUVA was confirmed in this study (12-14). Over 60% of lymphocytes
displayed phosphatidylserine on their cell surface 24 hr after PUVA treatment, and
between 70% and 90% of lymphocytes entered a late stage of apoptosis 48 hr after
treatment. In fact, as early as 2 hr after PUVA treatment, 21% of lymphocytes displayed
phosphatidylserine, illustrating the activation of an immediate pre-programmed apoptotic
pathway (16, 17).

5.4. Indirect Effects of PUVA
The transcription factor NF-κB is a key regulator of many genes associated with
DC immunogenicity, and many inflammatory stimuli, such as LPS, TNF-α, and IL-1,
induce DC maturation through activation of the NF-κB pathway (107). Therefore, it is
not surprising that many immunosuppressive stimuli act by inhibiting NF-κB, and GILZ
is a direct inhibitor of NF-κB in T-lymphocytes (72), macrophages (62), and DCs (59,
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69). In addition, the exposure of DCs to apoptotic cells has been shown to inhibit NF-κB
(108), leading to a truncation in DC maturation and polarization towards a tolerogenic
functional state (109). This present study implicates GILZ as the downstream molecular
mediator transmitting the immunosuppressive effects of apoptotic cells, ultimately
resulting in NF-κB inhibition. MoDCs exposed to ApoL up-regulated GILZ in an
apoptotic cell dose-dependent manner, and acquired a tolerogenic phenotype and
function. The tolerogenic functional profile of these cells was diminished after transient
knockdown of GILZ with siRNA.
The immunosuppressive elements associated with apoptotic cells have not been
fully elucidated, but likely involve unique molecular characteristics of the apoptotic cell,
the production of tolerogenic factors, the kinetics of cell death, and the nature of the
apoptotic-inducing stimulus (110). Apoptotic lymphocytes display phosphatidylserine on
their surface soon after apoptosis is initiated (83), and this process triggers recognition
and removal by APCs (82). Receptors involved in the recognition and internalization of
apoptotic bodies include phosphatidylserine receptors (TAM receptors) (84), the
thrombospondin receptor (CD36) (78, 79), the vitronectine receptor (αVβ3 integrin) (74),
and other scavenger receptors (78). Notably, both phosphatidylserine (79), and antiCD36 (83), are capable of transmitting immunosuppressive signals from apoptotic cells.
This suggests that the exposure of phosphatidylserine and other molecules recognized by
scavenger receptors may comprise the bulk of these signals. Recently, membrane blebs
containing high levels of phosphatidylserine were observed to originate from apoptotic
lymphocytes after PUVA treatment,, and these membrane blebs contained an
immunosuppressive surface composition of antigens, (111). It is reasonable that the
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recognition and internalization of membrane blebs constituted the major
immunosuppressive signal from apoptotic lymphocytes and induced GILZ expression in
this study.
In addition, lymphocytes release both IL-10 (112) and TGF-β (113) as they
undergo controlled apoptosis, and UV-irradiated lymphocytes have also been observed to
produce IL-10 (114). It remains a possibility that GILZ induction may have resulted
from IL-10 release by ApoL, with subsequent paracrine signaling within cell culture. In
contrast, rapid lymphocyte apoptosis, leading to secondary necrosis, results in the release
of numerous DAMPs, including high-mobility group box-1 (HMGB-1), heat shock
proteins, uric acid, and mammalian DNA, all of which are highly immunogenic (110).
Thus the extent of cell death and the kinetics of apoptotic induction likely play a key role
in determining which types of signals are transmitted (110). Of interest, lymphocytes in
this study exhibited widespread apoptotic death following PUVA exposure, but first
entered through a distinct early apoptotic stage in which their cellular membranes were
intact and DAMPs were presumably not released in significant quantities (see Figure
4A). Moreover, there was no indication of lymphocyte necrosis preceding apoptosis,
providing additional circumstantial evidence that MoDCs were capable of processing
these cells efficiently before they entered stages of late apoptosis.
An additional interesting hypothesis is that reactive oxygen species generated
from PUVA exposure may modify HMGB-1 and other DAMPs, abolishing their intrinsic
immunogenicity once released from the dying cell (110). In support of this claim,
Kazama et al. demonstrated that the induction of tolerance by apoptotic cells requires
caspase-dependent oxidation of HMGB-1 (115). Given that PUVA activates an early
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apoptotic pathway in lymphocytes involving caspase-3, -8, and -9 (15-17), apoptotic
lymphocytes induced by PUVA may be uniquely conditioned to induce tolerance through
the oxidation and neutralization of HMGB-1 (115). A limitation of this present study is
that only the exposure of MoDCs to ApoL was linked with GILZ induction. A
requirement for cell-contact between DCs and ApoL, or the contributions from
internalization, release of IL-10 or DAMPs, and other signaling pathways were not fully
investigated. Additional studies will be required to elucidate precisely how cell-to-cell
contact, IL-10 production by PUVA-treated cells, and the internalization of apoptotic
bodies contribute to the induction of GILZ.
One intriguing possibility is that TAM receptor signaling may provide the missing
link between cell surface recognition of apoptotic cells and GILZ induction. TAM
(Tyro3, Axl, Mer) receptors are a family of tyrosine kinases capable of transducing
immunosuppressive signals from apoptotic cells (84, 116). TAM receptors were
originally demonstrated to inhibit TLR-induced inflammation in a tripartite model
postulated by Rothlin et al. (117). This model asserts that TLR ligation initially leads to
the production of cytokines that promote inflammation and host defense (117). In the
second part of the model, these pro-inflammatory cytokines amplify the inflammatory
response through feed-forward signaling (117). In the final stage, these same cytokines
induce TAM receptor activation as a negative feedback mechanism to inhibit the
inflammatory response (117). This system is postulated to enable the immune system to
quickly launch an immunogenic, pro-inflammatory response that is ensured to be selflimiting and non-detrimental to the host through inhibitory signaling from TAM receptor
activation (117).
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TAM receptors also have an important role in apoptotic cell homeostasis (84).
TAM-deficient cells fail to properly internalize apoptotic cells and membranes (84), and
autoimmune disease universally develops in TAM knockout mice, likely as a result of the
aberrant clearance of apoptotic cells by APCs (116, 118). Growth arrest-specific 6
(GAS6) and protein S, two TAM receptor ligands produced by macrophages and DCs,
bind phosphatidylserine and form a molecular bridge between the apoptotic cell
displaying phosphatidylserine and the APC expressing TAM receptors (84, 117, 118).
Phosphatidylserine also stabilizes the interaction between the TAM receptor and its
ligands, preventing dissociation and ensuring strong and persistent down-stream
intracellular signaling through the TAM receptor (84, 116-118). In this model,
phosphatidylserine is the only immunosuppressive stimuli carried by an apoptotic cell
(84), and the internalization or clearance of apoptotic bodies would not be absolutely
required for tolerance induction.
The net result of TAM receptor signaling is inhibition of the same proinflammatory signaling pathways as GILZ, including NF-κB, MAPK and EKR-1/2 (84,
117-119). Specifically, signaling through Mer, a TAM receptor expressed on DCs,
inhibits LPS-induced NF-κB activation and reduces IL-12 and TNF-α production (120,
121). Curiously both GILZ and TAM knockout mice have a similar phenotype in the
testes, characterized by defects in the phagocytic clearance of apoptotic cells, a complete
loss of the germ cell lineage, and male sterility (59, 84). Given the central importance of
TAM receptors in clearing apoptotic bodies (84, 119), transmitting their
immunosuppressive signals (120, 121), and inhibiting pro-inflammatory signaling
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pathways after TLR-ligation (116, 117), the possibility that TAM receptor signaling leads
to the downstream induction of GILZ should be further investigated.
An unanswered question from this study is whether interactions between
apoptotic MoDCs and viable MoDCs may have been responsible for the induction of
GILZ observed in PUVA-DC cultures. PUVA-DCs were cultured at low cell density and
were relatively adherent to the plastic culture well. Nevertheless, the possibility remains
that a small percentage of apoptotic MoDCs in culture may have generated membrane
blebs with high levels of phosphatidylserine (111), capable of diffusing and bridging the
distance between individual cells to transmit immunosuppressive signals.
Of note, the time course for GILZ induction differed greatly between Dex-DCs
and PUVA-DCs (see Figure 1E). Dexamethasone induced maximum GILZ expression
within 2 hr of PUVA treatment, and the expression remained elevated for at least 72 hr in
culture. This observation is consistent with the known pharmacokinetics of
glucocorticoids. Dexamethasone, like all glucocorticoids, is lipid soluble and rapidly
diffuses into the cytoplasm of cells where it associates with the cytosolic glucocorticoidreceptor (70, 71). This complex then travels to the nucleus and binds to the
glucocorticoid-response elements upstream of the GILZ promoter, thereby inducing
GILZ mRNA transcription (70, 71). In contrast, PUVA-DCs did not demonstrate
significant up-regulation of GILZ until 8 hr after PUVA treatment, and the maximum
expression level occurred only after 24 hr. This suggests a fundamental difference
between dexamethasone and PUVA treatment in regards to the mechanism leading to
GILZ induction. The cellular events mediating the direct effects of PUVA on MoDCs,
including the cellular stress response and DNA repair pathway activation, may take time
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before GILZ mRNA is ultimately transcribed. Alternatively, this observation may be
demonstrating that MoDCs must first enter the apoptotic pathway, and then be
recognized and internalized by viable MoDCs, before the induction of GILZ occurs.
Nevertheless, GILZ was induced at high levels in MoDCs treated with PUVA
doses that did not result in an increase in the percentage of early apoptotic MoDCs above
the level observed in untreated cultures (see Figure 2B). However, if the
immunosuppressive signals delivered by an apoptotic DC and an ApoL are not
equivalent, then it may be possible for far fewer apoptotic DCs to mediate a tolerogenic
effect. Indeed, there is evidence that there may be quantitative differences between
various types of apoptotic cells. It is well known that mice with defects in apoptotic
pathways mediated through Fas and FasL develop autoimmune disease (122).
Specifically inhibiting DC apoptosis, but not lymphocyte apoptosis, leads to autoimmune
disease, suggesting a unique role for DC apoptosis in the maintenance of tolerance (123).
Moreover, when viable DCs internalize apoptotic, but not necrotic DCs, they become
resistant to LPS maturation (124) and generate antigen-specific Foxp3+ Tregs (124, 125).
The induction of Tregs is a direct result of TGF-β1 secretion by viable DCs (122),
previously shown to be necessary for the differentiation of naïve T-lymphocytes into
Tregs (42, 43).
Macrophages also secrete TGF-β1 after ingesting apoptotic cells, and this TGFβ1 production is dependent on phosphatidylserine (126). Interestingly however, the
internalization of apoptotic splenocytes by viable DCs does not induce TGF-β1
production (124, 125). Given that apoptotic splenocytes display phosphatidylserine, this
observation suggests a phosphatidylserine-independent mechanism for TGF-β1 release
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by viable DCs after internalization of apoptotic DCs, as well as the presence of key
molecular differences between apoptotic DCs and non-DC apoptotic cells (122, 127).
The unique receptors mediating TGF-β1 secretion after the uptake of apoptotic DCs are
unknown, but may involve highly specific receptors, possibly αβ integrins, only
expressed on the surface of apoptotic DCs (122, 127). The production of TGF-β mRNA
transcripts in this present study were higher in PUVA-DCs than in untreated MoDCs
exposed to ApoL (3.4-fold vs. 2.1-fold above untreated MoDCs, respectively), suggesting
that the internalization of apoptotic MoDCs by viable MoDCs may have played a role in
the induction of GILZ and transcription of TGF-β mRNA.
DCs expressing GILZ at high levels have been shown to generate antigen-specific
Tregs, and GILZ, IL-10 and TGF-β are all necessary for this induction (42, 43, 69).
Although this study did not specifically analyze Treg responses, MoDCs expressing
GILZ increased production of IL-10 at both the protein and mRNA level, and increased
TGF-β at the mRNA level. Given that an intravenous infusion of PUVA-treated
apoptotic cells induces antigen-specific Tregs in vivo (31, 46, 47), it is reasonable that
MoDCs expressing GILZ, and secreting IL-10 and TGF-β, would also be capable of
inducing Tregs. Further studies will be needed to explore the possibility that MoDCs
treated with PUVA, and/or exposed to ApoL, are capable of inducing Tregs in a similar
fashion as Dex-DCs (69).
Both PUVA, and/or exposure to ApoL, induced GILZ expression to levels
comparable with previous reports in human DCs (see Figure 5B) . Up-regulation of
GILZ mRNA was confirmed by increased levels of GILZ protein, as assessed by
intracellular flow cytometric analysis (see Figure 5C). However, the increase in GILZ

58
protein level did not follow the same trend as for GILZ mRNA up-regulation. This is
most likely due to the fact that protein expression was only analyzed 24 hr after
treatment, and the kinetics of both GILZ mRNA and protein up-regulation and stability
varied depending on the specific type of treatment. Dex-DCs maximally up-regulated
GILZ mRNA within 2 hr of treatment (see Figure 1E), and demonstrated the highest
protein level after 24 hrs. In contrast, PUVA-DCs maximally up-regulated GILZ mRNA
24 hr after treatment, and therefore the protein level was found to be lower than that of
Dex-DCs at the same time point. Lastly, MoDCs exposed to ApoL would be expected to
have the slowest induction of GILZ mRNA and protein, given the requirement for
phosphatidylserine exposure on lymphocytes, followed by recognition and processing by
MoDCs. This may help explain why after 24 hr the GILZ mRNA levels were highest in
MoDCs exposed to ApoL, but the proteins levels did not yet reflect this elevated mRNA
expression. It would be useful to assess GILZ protein induction at earlier and later time
points to more definitively clarify the kinetics of protein induction.
In addition, MoDCs expressing high levels of GILZ produced more IL-10 (see
Figure 6A), and produced lesser amounts of various pro-inflammatory cytokines,
including IL-12, IL-6, TNF-α, and IFN-γ (see Figure 6B, 6C). GILZ was necessary for
the conversion to a tolerogenic cytokine profile, as evidenced by a reduction in IL-10
production, and an increase in IL-12p70 production, following transient siRNA-mediated
GILZ knockdown (see Figure 7B, 7C). IL-12, IL-6, TNF-α, and IFN-γ are all
inflammatory mediators released by immunogenic MoDCs in response to TLR ligation
(34, 35). These cytokines polarize the immune response towards an inflammatory state,
and help differentiate effector T-lymphocyte subsets and support their functions (34, 35).
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MoDCs expressing high levels of GILZ also produced lesser amounts of various proinflammatory chemokines, including IL-8, MCP-1 (CCL2), MIP-1β (CCL4), and
RANTES (CCL5) (see Figure 6D, 6E). These data support an earlier study in a
monocytic cell line (THP-1), showing that GILZ expression reduced the production of
both MIP-1α (CCL3) and RANTES (CCL5) (62). These chemokines are also produced
by immunogenic MoDCs in response to TLR ligation, and they function as chemotactic
factors, recruiting immune cells such as neutrophils, natural killer cells and Tlymphocytes to sites of inflammation or infection (34, 35).
This dualistic pattern of cytokine release, with reduced production of proinflammatory cytokines and increased production of anti-inflammatory cytokines, is
central to UVB-induced, PUVA-induced, and ECP-induced immunomodulation (1).
UVB induces IL-10 release from keratinocytes (128), and PUVA has been shown to
significantly reduce the production of IL-6, IL-8, IL-1β and TNF-α (129). Likewise, in
patients with chronic GVHD, ECP increases production of IL-10 (21, 51, 52) and IL-1Ra
(21, 51, 52), and DCs cultured post-ECP produce no detectable levels of IL-1, IL-6 or IL12 (21). While the general trend for reduced pro-inflammatory molecule production held
true for all MoDCs demonstrating significant GILZ up-regulation, some groups did not
achieve statistically significant reductions for individual cytokines and chemokines. This
was most likely due to biological variability between individuals, and given a larger
sample size, all groups would have likely achieved statistically significant reductions for
all cytokines and chemokines. Lastly, PUVA could theoretically have globally
suppressed the production of all pro-inflammatory molecules, however this is highly
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unlikely given increased IL-10 production in the same MoDCs displaying reduced proinflammatory molecule production.

5.5. Implications for Extracorporeal Photochemotherapy
The results presented in this in vitro model of ECP have potentially important
implications for the in vivo mechanisms operating after ECP. The vast majority of ECPtreated cells travel to either the spleen or liver following intravenous infusion (81).
Splenic marginal zone DCs ingest circulating apoptotic cells as soon as 1 hr after
intravenous injection (130), and in a different report, the highest percentage of splenic
immature DCs with internalized apoptotic cells was detected 18 hr after injection (31).
Although the mechanisms directing ECP-treated cells towards these anatomical locations
are not known, the marginal zone of the spleen, in particular, contains abundant APCs
capable of interacting with T-lymphocytes circulating through the spleen (81). It is
conceivable that reinfusion of ECP-treated ApoL, and subsequent in vivo interactions
with untreated tissue-resident splenic DCs, may induce GILZ expression and generate
tolerogenic DCs capable of mediating antigen-specific immunosuppression. This would
be analogous to the in vivo induction of GILZ within tissue-resident DCs after systemic
glucocorticoid administration (59). It also points toward the marginal zone of the spleen
as being the central anatomical location for tolerance induction elicited by ECP-treated
apoptotic cells. Moreover, the liver has been broadly implicated as an anatomically
important site for tolerance induction (110, 131), as antigen-triggered apoptosis results in
the elimination of lymphoid cells by the liver (132).
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In addition, the ECP procedure itself, through a combination of leukapheresis,
flow dynamics on the plastic exposure plate, and interactions with platelets or other
serum proteins, induces monocyte-to-DC differentiation (29). It is plausible that the
effects of PUVA revealed by our in vitro study initiate a chain of events culminating in
GILZ induction and the modulation of differentiating MoDCs. Interestingly, PUVA-DCs
exposed to ApoL up-regulated GILZ to higher levels than either untreated MoDCs
exposed to ApoL, or PUVA-DCs alone, suggesting a synergistic effect between PUVA
treatment and ApoL exposure (see Figure 5B). It is tempting to speculate that PUVA
may pre-condition MoDCs for the subsequent processing of ApoL, possibly by increasing
the phagocytic capacity of differentiating MoDCs by up-regulating thrombospondin
receptors (CD36) (133), TAM receptors, or other scavenger receptors. Given the
synergism observed between PUVA-DCs and exposure to ApoL in regards to GILZ
induction, MoDCs produced during the ECP procedure may also be uniquely preconditioned by PUVA treatment to generate tolerogenic immune responses in vivo.
In clinical use, patients’ PBMC are exposed to UVA light as they pass
extracorporeally through a thin exposure plate (7). While the centrifugation process to
isolate PBMC from other cell types is quite efficient, there are still contaminating red
blood cells flowing through the exposure plate that are capable of absorbing UVA
radiation. Moreover, assuming laminar flow, cells in the center of the plate will flow
faster than cells on the periphery. As a result of the plate’s small, but non-zero thickness,
laminar flow mechanics, and red cell contamination, it is possible that populations of
monocytes, DCs, and differentiating MoDCs may be exposed to different amounts of
UVA radiation from a fixed UVA light source. Therefore, sub-populations of APCs may
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be modulated in subtle ways during the procedure, and may have different in vivo effects
after reinfusion. Extrapolating from the data presented in this study, if a MoDC received
a slightly smaller amount of UVA light energy, it may induce GILZ expression and be
polarized towards the tolerogenic pathway. If a second MoDC received slightly more
UVA light energy, it may enter the apoptotic pathway after reinfusion into the patient.
The net result would be a complex interaction of cells in vivo, where MoDCs modulated
to varying degrees would be mediating the final clinical response.
Two recent studies highlight the pivotal role for DCs in mediating in vivo
tolerogenic responses after ECP. Firstly, Divito et al. challenged the conventional view
that tolerogenic DCs suppress allograft rejection by interacting directly with anti-donor
T-lymphocytes in vivo (134). This group demonstrated that an infusion of tolerogenic
DCs prolonged heart allograft survival not by directly interacting with T-lymphocytes in
vivo, but by being re-processed by recipient DCs (134) . The authors suggest that
infusions of DCs are short-lived in vivo, and act as antigen-transporting cells, rather than
APCs, to prolong allograft survival (134). This model supports the hypothesis that GILZ
induction within tissue-resident DCs may be the initial event leading to tolerogenic
responses observed after reinfusion of ECP-treated cells. Furthermore, it lends credence
to the possibility that a small percentage of ECP-treated MoDCs undergoing early
apoptosis are transmitting distinct tolerogenic signals (122-125) leading to GILZ upregulation, and that the immunosuppressive signals are not transmitted solely by ApoL.
Secondly, a murine model of contact hypersensitivity demonstrated that the cellmediated inhibition of a hapten immune response was lost when PUVA-treated
splenocytes and lymph node cells from dinitrofluorobenzene (DNFB)-sensitized donors
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were depleted of CD11c+ DCs prior to their adoptive transfer into naïve mice (31). The
tolerance was antigen-specific, as the naïve recipient mice retained the ability to properly
respond to an unrelated hapten (31). Strikingly, there was still cell-mediated and antigenspecific inhibition of the same hapten immune response when PUVA-treated splenocytes
and lymph node cells from DNFB-sensitized donors were instead depleted of CD3+
lymphocytes (31). This implies, in this hapten model, that PUVA-treated CD11c+ DCs
are the primary and relevant cellular target for ECP in mediating tolerogenic responses in
vivo.
Furthermore, the adoptive transfer of cells from primary recipients that had
received ECP-treated cells significantly suppressed the DNFB response in secondary
recipients, but the transfer capability was lost when the cells were depleted of CD4+ or
CD25+ populations (31). Taken together, these results demonstrate that not only are the
CD11c+ DCs the primary cellular target of ECP, but they induce antigen-specific
CD4+CD25+ Tregs in vivo (31). The hapten model does have the limitation that the
antigen must be physically linked to the apoptotic cell, and only APCs retain this capacity
for a long enough time in vivo to transmit meaningful tolerogenic signals (31). In other,
non-haptenated models, ECP-treated APCs may not be as critical for the induction of
tolerance, as has been demonstrated with other in vivo models of ECP (45-47).
Returning to the fundamental mystery surrounding ECP’s clinical efficacy in
CTCL (7), GVHD (8), allograft rejection (9), and autoimmune disease (10), it is
worthwhile to consider how differences in immune responses may result from the
intrinsic properties of patients’ circulating lymphocytes. Varying percentages of
malignant lymphocytes (known as Sézary cells) are present within peripheral blood in
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patients with CTCL (135). This percentage can be particularly high if the patient has the
leukemic variant of CTCL, known as Sézary syndrome (135, 136). Sézary cells are
fundamentally abnormal. They possess numerous genetic mutations, gene deletions, and
chromosomal translocations (137). They also have abnormal apoptotic pathways (138140), and are insensitive to many traditional T-lymphocyte mitogens (141). In contrast,
patients with GVHD, allograft rejection, and autoimmune disease, all have numerous
benign, auto-reactive circulating lymphocytes. These are fundamentally normal
lymphocytes performing their specialized functions, albeit they are targeting self-tissues
or allogeneic grafts and inflicting tissue damage in the process. As such, it is not
unreasonable to speculate that the responses of malignant Sézary cells and benign autoreactive lymphocytes to ECP may be vastly different, and translate into distinct immune
responses.
The kinetics of apoptotic induction, and the activation state of the apoptotic cell,
both play a key role in influencing the immunogenicity or tolerogenicity of the apoptotic
stimulus (110). Given their numerous genetic and apoptotic pathway abnormalities (137140), Sézary cells may rapidly undergo apoptosis in large numbers after ECP, effectively
outstripping the phagocytic capacity of DCs to ingest and process them. Sézary cells
would then become secondarily necrotic and release numerous DAMPs and
immunogenic factors (115). Upon reinfusion into the patient, apoptotic Sézary cells, in
combination with these pro-inflammatory mediators, would polarize an immunogenic Th1
and cytotoxic T-lymphocyte immune response to target and eradicate the malignant cells
(136). Alternatively, given aberrant apoptotic pathways, Sézary cells may not possess the
capacity to oxidize HMGB-1 in a caspase-dependent fashion, resulting in an overly
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immunogenic apoptotic cell (115). It has also been shown that anti-CD3-activated Tlymphocytes express CD154, which converts a normally tolerogenic apoptotic
lymphocyte into an immunogenic stimulus (142). Interestingly, Sézary cells express
many activation markers, including CD45RO (135), CD25 (135), and STAT3 (143), and
the malignant cells’ persistent state of activation may play a role in the pathogenesis of
CTCL (135). In summary, the rapid and wide-spread induction of apoptosis, release of
DAMPs, and the persistent activation state of Sézary cells, may all play a role in
polarizing an immunogenic response after ECP in patients with CTCL.
On the other hand, auto-reactive T-lymphocytes may undergo a controlled, slower
apoptotic cell death after ECP, producing immunosuppressive membrane blebs (111) that
are efficiently cleared by DCs before becoming secondarily necrotic and releasing
DAMPs. The net in vivo effect would be the induction of GILZ within tissue-resident
DCs, possibly in the spleen or liver, the subsequent generation of tolerogenic DCs, and
the induction of antigen-specific immune tolerance through Treg generation.
Investigating the differing susceptibilities of Sézary cells from CTCL patients, and autoreactive lymphocytes from GVHD patients, including the kinetics of cell death following
ECP and the release of pro-inflammatory mediators, may shed light on this central
unanswered question regarding the immunodulation observed after ECP.

5.6. Concluding Remarks
In conclusion, PUVA acts directly, and indirectly via the generation of ApoL, to
induce GILZ expression and polarize MoDCs towards a tolerogenic phenotype and
functional state. MoDCs expressing GILZ are characterized phenotypically by reduced
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expression of co-stimulatory molecules and resistance to full maturation by LPS.
MoDCs expressing GILZ are characterized functionally by increased production of
immunosuppressive cytokines, and reduced production of pro-inflammatory cytokines
and chemokines. GILZ is necessary for the PUVA-mediated generation of this
tolerogenic cytokine profile in MoDCs, as IL-10 production was decreased and IL-12
production was increased following transient siRNA-mediated knockdown of GILZ.
This study provides a molecular explanation for the immunosuppressive signals
delivered by PUVA and apoptotic cells, and contributes towards explaining how ECP can
generate antigen-specific immunosuppression. It also links PUVA and apoptotic cells
with glucocorticoids, IL-10 and TGF-β. All share a common mechanism for immune
regulation at the level of GILZ induction and inhibition of NF-κB and other proinflammatory signaling pathways. The critical difference between ECP and
glucocorticoid therapy lies in the steroid-sparing action of both PUVA and apoptotic
cells. ECP induces antigen-specific immunomodulation, thereby protecting the patient
from the side effects of chronic steroid therapy, including an increased rate of infection
and malignancy, adverse metabolic effects, and detrimental effects on bone and
endocrine health (70, 71).
It will be important to determine whether the two PUVA-mediated methods of
GILZ induction that we have identified can form the basis for novel therapeutic design.
If the answer is affirmative, then over 20 years of clinical experience with ECP will be a
lucrative source for these derived advances. ECP could form the basis for strategies
aimed at selectively inducing GILZ expression in DCs, representing a promising
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therapeutic avenue to promote the induction and maintenance of tolerance in GVHD,
allograft rejection, and autoimmune diseases (144).
Furthermore, DC vaccines are capable of generating proficient anti-tumor
responses in vitro, but have failed to produce durable clinical responses. A principle
reason for this universal shortcoming is the inhibitory microenvironment established by
tumors that provides a powerful, suppressive influence on the anti-tumor immune
response (145). A recent study even revealed that the tumor microenvironment induced
GILZ expression within DCs found at the site of tumors, thereby suppressing their antitumor immunogenic activity (145). Interestingly, blocking GILZ within DC vaccines
prolonged the survival of mice with a pre-existing tolerogenic tumor microenvironment
(145). This study suggests that selectively blocking GILZ activation may represent a
novel strategy to translate the in vitro anti-tumor responses observed with DC vaccines
into durable in vivo clinical responses. Continued investigation into the mechanism of
ECP may shed light on how to modify and enhance the therapy to selectively activate
GILZ in diseases of auto-reactive lymphocytes, and turn off GILZ in the design of DC
vaccines for solid-tumor immunotherapy.
From reports of the ancient Egyptians using the Ammi majus plant growing
alongside the Nile River to treat skin disease, to the characterization of its active
component as a psoralen, UVA radiation combined with photosensitizing psoralens has
remained an effective dermatologic therapy. ECP has the potential to polarize DCs
towards a tolerogenic or immunogenic pathway by simply switching GILZ on or off
depending on which type of immunomodulation is desired for a given disease. It is
remarkably appealing to consider the simplicity of using a small molecule and UV
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radiation to selectively stimulate the immune response to target cancer in CTCL,
malignant melanoma, and other solid-organ tumors, and selectively suppress the immune
response in GVHD, solid-organ transplant rejection, and autoimmune disease.
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